

The sleep-wake distribution contributes to the peripheral rhythms in PERIOD-2

Marieke M.B. Hoekstra^{1,2*}, Maxime Jan^{1*}, Yann Emmenegger¹, Paul Franken¹

¹Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

²current address: UK Dementia Research Institute at Imperial College London, Division of Brain Sciences, London, United Kingdom

* share first authorship on this work

Abstract

In the mouse, *Period-2* (*Per2*) expression in tissues peripheral to the suprachiasmatic nuclei (SCN) increases during sleep deprivation and at times of the day when animals are predominantly awake spontaneously, suggesting that the circadian sleep-wake distribution directly contributes to the daily rhythms in *Per2*. We found support for this hypothesis by recording sleep-wake state alongside PER2 bioluminescence in freely behaving mice, demonstrating that PER2 increases during spontaneous waking and decreases during sleep. The temporary reinstatement of PER2 rhythmicity in behaviorally arrhythmic SCN-lesioned mice submitted to daily recurring sleep deprivations substantiates our hypothesis. Mathematical modelling revealed that PER2 dynamics can be described by a damped harmonic oscillator driven by two forces: a sleep-wake-dependent force and a SCN-independent circadian force. Our work underscores the notion that in peripheral tissues the clock gene circuitry integrates sleep-wake information and could thereby contribute to behavioral adaptability to respond to homeostatic requirements.

Keywords: circadian rhythm, sleep, waking, *Period-2*, bioluminescence, locomotor activity, modeling, kidney, cortex.

30 Introduction

31 The sleep-wake distribution is coordinated by the interaction of a circadian and a homeostatic
32 process (Daan et al., 1984). The biological substrates underlying the circadian process are
33 relatively well understood: circadian rhythms in overt behavior of mammals are generated by
34 the suprachiasmatic nuclei (SCN) located in the hypothalamus (Hastings et al., 2018). At the
35 molecular level, so called 'clock genes' interact through negative transcriptional/translational
36 feedback loops (TTFLs), where the CLOCK/NPAS2:ARNTL (BMAL1) heterodimers drive the
37 transcription of their target genes, among them the *Period* (*Per1,2*) and *Cryptochrome* (*Cry1,2*)
38 genes. Subsequently, PER and CRY proteins assemble into repressor complexes that inhibit
39 CLOCK/NPAS2:ARNTL-mediated transcription, including their own. The resulting reduction of
40 the repressor complex allows a new cycle to start. This feedback loop, present in almost each
41 cell of the mammalian body, interacts with other molecular pathways, together ensuring a
42 period of ~24h (Hastings et al., 2018). The SCN synchronizes peripheral clock gene
43 expression rhythms through its rhythmic behavioral, electrical, and humoral output generated
44 across the day (Schibler et al., 2015).

45 Accumulating evidence suggests that, perhaps surprisingly, clock genes are also involved in
46 the homeostatic aspect of sleep regulation (Franken, 2013). This is illustrated by the sleep-
47 deprivation (SD) induced increase in the expression of the clock gene *Per2* in tissues
48 peripheral to the SCN, including the cerebral cortex, liver, and kidney (Curie et al., 2013, 2015;
49 Franken et al., 2007; Maret et al., 2007). Moreover, the highest level of peripheral *Per2*
50 expression is reached after the time of day mice were awake most, suggesting that also during
51 spontaneous periods of waking *Per2* expression accumulates. Accordingly, lesioning of the
52 SCN, which eliminates the circadian sleep-wake distribution, attenuates the circadian
53 amplitude of clock gene transcripts and proteins in peripheral tissues (Akhtar et al., 2002; Curie
54 et al., 2015; Tahara et al., 2012; Sinturel et al., 2021). Together, these studies suggest that
55 sleeping and waking are important contributors to clock gene expression but dissecting the
56 contribution of the sleep-wake distribution and circadian time is challenging, because the two
57 change in parallel.

58 By simultaneously recording electroencephalogram (EEG), electromyogram (EMG), locomotor
59 activity and PER2-dependent bioluminescence signals from cortex and kidney in freely
60 behaving mice, we established that the circadian sleep-wake distribution importantly
61 contributes to the daily rhythmic changes in central and peripheral PER2 levels. To further test
62 this hypothesis, we predicted that i) in behaviorally arrhythmic SCN-lesioned (SCNx) mice,
63 daily recurring SDs mimicking a circadian sleep-wake distribution, will temporarily reinstate
64 high amplitude PER2 bioluminescence rhythms and ii) in intact rhythmic animals, reducing the
65 amplitude of the circadian sleep-wake distribution will result in a reduced amplitude of PER2

66 rhythms. While daily SDs indeed enhanced the amplitude of peripheral PER2 rhythms in SCNx
67 mice, the protocol used to reduce the amplitude of the sleep-wake distribution did not reduce
68 PER2 amplitude in all mice. To reconcile the sleep-wake driven and circadian aspects of PER2
69 dynamics, we implemented a mathematical model in which waking represents a force that sets
70 in motion a harmonic oscillator describing PER2 dynamics, and found that the sleep-wake
71 distribution, also under undisturbed conditions, is an important contributor to the daily changes
72 in PER2 bioluminescence. Moreover, we discovered a second, SCN and sleep-wake
73 independent force with a circadian period that underlay the residual circadian PER2 rhythms
74 in SCNx mice, and that the phase relationship between these two forces is important for
75 predicting the amplitude response in PER2 rhythms to sleep-wake perturbations.

76

77 **Results**

78 To quantify PER2 levels, we used mice expressing a knock-in (KI) construct encoding a fused
79 PER2::LUCIFERASE (PER2::LUC) protein and in which changes in emitted bioluminescence
80 can be used as proxy for changes in PER2 protein levels (Yoo et al., 2004). *Per2::Luc* KI mice
81 have been used to follow clock gene expression *in vivo* (Curie et al., 2015; Ohnishi et al., 2014;
82 Tahara et al., 2012; van der Vinne et al., 2018). However, in these studies mice had to be
83 anaesthetized for each measurement, while in the set-up used in our study [RT-Biolumicorder
84 (C. Saini et al., 2013)], we assessed PER2-bioluminescence continuously in freely moving
85 mice, in central and peripheral tissues. For the central quantification of bioluminescence, we
86 used mice in which the PER2::LUC construct was back-crossed onto a C57BL/6J (B6)
87 background (see Methods). For the experiments that quantified bioluminescence in the
88 periphery, we used hairless SKH1 mice carrying the *Per2::Luc* KI construct, because lack of
89 fur allows for the unobstructed measurement of emitted photons (see also Suppl. Fig. 1). Under
90 standard LD12:12 conditions, SKH1 mice exhibited sleep-wake patterns characteristic of mice,
91 i.e. during the light phase they spent more time in both Non-Rapid-Eye-Movement (NREM)
92 sleep and REM sleep relative to the dark phase, the latter being their habitual active phase.
93 Moreover, they showed the typical sleep homeostatic response to a 6h SD during the first 18h
94 of recovery, both in sleep time and EEG delta power, although the increase in REM sleep did
95 not reach significance levels (Suppl. Fig. 2).

96 In two pilot experiments we optimized our experimental set-up. We established that the most
97 important source contributing to the peripheral bioluminescence signals in the SKH1 mice are
98 the kidneys (Suppl. Fig. 3A). We have previously shown that the central bioluminescence
99 signal obtained in B6 mice is of cortical origin (Curie et al. 2015). By using mice constitutively
100 expressing luciferase (Y.-A. Cao et al., 2004), we determined that its substrate luciferin is best

101 delivered through implantable osmotic mini-pumps compared to administration through the
102 drinking water. Under the latter condition, strong daily rhythms in bioluminescence were
103 observed, likely as a result of rhythms in drinking behavior, thereby driving luciferin availability
104 (Suppl. Fig. 3B). To record peripheral bioluminescence, we implanted mice subcutaneously
105 with mini-pumps in a short (5min) intervention. To record central bioluminescence, luciferin
106 was administered centrally through a cannula connected to a subcutaneously placed mini-
107 pump, requiring stereotactic surgery. In addition, the skull was thinned and equipped with a
108 glass cone facilitating passage of photons through the skull (Curie et al. 2015; see Methods
109 for details).

110

111 SLEEP-WAKE STATE AFFECTS PER2 BIOLUMINESCENCE

112 It now has been well documented that enforced wakefulness affects *Per2* mRNA and protein
113 levels in various tissues and mammalian species (Franken, 2013; Hoekstra et al., 2019; Möller-
114 Levet et al., 2013; Vassalli & Franken, 2017), but it is not known whether circadian rhythms in
115 spontaneous sleep-wake behavior contribute to the daily changes in PER2 levels. To address
116 this question, we equipped *Per2::Luc* KI B6 and SKH1 mice (n=6 and 5, respectively) with
117 wireless EEG/EMG recorders and monitored simultaneously sleep-wake state, PER2
118 bioluminescence and locomotor activity under constant darkness (DD; see Suppl. Fig. 1). With
119 this set-up, we reproduced the circadian changes in PER2 bioluminescence as well as the
120 response to a 6h SD (Fig. 1A) as described previously (Curie et al., 2015) (see material and
121 methods for explanation of the SD procedure). Similar to what was observed in that publication,
122 SD elicited a tissue-specific response, with an immediate increase in central PER2-
123 bioluminescence after SD, while in the periphery the response was delayed and PER2
124 bioluminescence increases were observed in the 2nd and 5th hour of recovery (Fig. 1A). In
125 addition to these direct effects on PER2 bioluminescence within the 1st 6h of recovery, the SD
126 also caused a long-term reduction of rhythm amplitude during both recovery days; i.e. the first
127 (REC1) and last (REC2) 24h period of recovery. In the periphery this decrease amounted to
128 ca. 30% on both days [REC1: 17.5-41.1%; REC2 18.7-42.4%, 95% confidence intervals (95%-
129 CI)]. In the central recordings PER2-bioluminescence amplitude decreased significantly during
130 REC1 [32% (10.2-54.5%)], whereas the decrease during REC2 [22% (0.06-44.8%)] no longer
131 reached significance levels [linear mixed model with fixed conditional effect ('BSL', 'REC1',
132 'REC2') and random intercept effect ('Mouse'); Periphery: BSL vs. REC1 p=0.0014; vs. REC2
133 p=0.0011; Central: BSL vs. REC1 p=0.022; vs. REC2 p=0.082; sinewave fitted baseline
134 amplitudes: periphery 0.258 (0.15-0.36); central 0.193 (0.08-0.31 a.u.)]. This long-term
135 reduction of PER2-bioluminescence is reminiscent of the long-term SD effects on rhythm




Figure 1: The sleep-wake distribution contributes to changes in PER2 bioluminescence. Red = peripheral bioluminescence, purple = central bioluminescence. **(A)** Left panels: PER2 bioluminescence measured in the first 30min of recovery (REC) after sleep deprivation compared to levels reached at this circadian time during baseline (BSL). Sleep deprivation elicited an acute response in central PER2 (lower bar graph: $t(4)=4.4$, $p=0.012$), but not in the periphery (upper bar graph, $t(4)=1.5$, $p=0.21$). Right panels: Under baseline conditions (lighter graphs, time 0-24h repeated three times, average of 48h baseline), PER2 bioluminescence showed a circadian rhythm both in the periphery (left) and central (right). Sleep deprivation from ZT0 to -6 (times under preceding LD conditions), affected PER2 bioluminescence during recovery (2-way rANOVA w/ Condition x Time, periphery: $F(41,164)=2.1$, $p=0.0007$; central: $F(41,164)=1.8$, $p=0.004$). Asterisks indicate significant differences assessed by post-hoc paired t-tests. Bioluminescence is expressed as a fraction of the individual average bioluminescence during the experiment and depicted in 1h intervals as $\text{mean} \pm \text{SEM}$ for 5 mice (peripheral and central). **(B)** A sleep-wake state recording (grey area plot represents wakefulness in consecutive 3-min intervals) combined with peripheral (red line, upper graph) and central PER2 bioluminescence (purple line, lower graph) in two mice during baseline. Note that besides the circadian oscillation in PER2 bioluminescence, there are marked increases and decreases in PER2 bioluminescence. The hypnogram (lower part of the graph) illustrates that the rapidly evoked changes in PER2 bioluminescence are related to periods of sleeping (S) and waking (W). This hypnogram is discontinuous as it depicts only the SW transitions selected in this mouse for the analysis in C. **(C)** Changes in PER2 bioluminescence associated with transitions from sleep to wake (top) and wake to sleep (bottom) of peripheral (left, $n=5$) and cortical (right, $n=6$) origin.

136 amplitude we observed for *Per2* expression and for other clock genes in the cortex (Hor et al.
137 2019).

138 Although a circadian modulation of PER2 bioluminescence of both peripheral and central origin
139 is evident (see Fig. 1B and Suppl. Fig. 4), we observed additional changes in bioluminescence
140 that occurred simultaneously with changes in sleep-wake state, indicating that PER2
141 bioluminescence increases during wake-dominated periods and decreases during sleep-
142 dominated periods in both tissues. To quantify this observation, transitions from sleep
143 (irrespective of sleep state) to wake and from wake to sleep were selected (see Material and
144 Methods for selection criteria). Examples of the selected transitions are indicated in Fig. 1B as
145 a hypnogram. A similar number of sleep-to-wake and wake-to-sleep transitions passed
146 selection criteria during the two-and-a-half baseline days (periphery: 31.2 ± 3.9 and 29.0 ± 3.9 ;
147 central: 25.6 ± 1.4 and 24.6 ± 1.4 , respectively; $\text{mean} \pm \text{SEM}$). Transitions obtained in mice in
148 which central bioluminescence was recorded were shorter (longest common wake period after

149 sleep-to-wake transitions: 39 vs. 57min; longest common sleep period after wake-to-sleep
150 transitions: 63 vs. 75min, for central and periphery, respectively). Although PER2-
151 bioluminescence increased during wakefulness and decreased during sleep in both tissues,
152 tissue-specific differences were observed (Fig. 1C). At sleep-to-wake transitions tissue
153 differences concerned an initial decrease in peripheral PER2-bioluminescence after wake
154 onset, followed by a steep increase saturating at 125%. In contrast, central levels of PER2
155 bioluminescence increased from the start and followed a linear time course throughout the
156 waking period. Despite these different dynamics, similar bioluminescence levels were reached
157 in both tissues. After wake-to-sleep transitions peripheral PER2 bioluminescence initially
158 increased before quickly decreasing and then leveling out at around 84% (Fig. 1C). In contrast,
159 the central signal decreased linearly throughout the sleep period reaching levels of 91% at the
160 end.

161 Taken together, two observations indicate that the sleep-wake distribution importantly
162 contributes to both central and peripheral PER2-bioluminescence dynamics: 1) enforcing
163 wakefulness has both acute and long-term effects on PER2 bioluminescence, 2) the changes
164 in PER2 bioluminescence at sleep-wake transitions demonstrate that also spontaneous
165 waking is associated with an increase in PER2 bioluminescence and sleep with a decrease,
166 and 3) that mice are spontaneously awake more when PER2 bioluminescence is high.

167 The central PER-bioluminescence signals tended to be noisier than peripheral signals [signal-
168 to-noise ratio: -1.15 ± 1.0 and 0.37 ± 1.0 dB, respectively; estimated on 3-min values in baseline
169 of the 6h-SD experiments according to (Leise et al., 2012)]. Moreover, the peripheral signal
170 was easier to obtain and minimally invasive to the animal. We therefore decided for the next
171 experiments, to focus on peripheral PER2 bioluminescence using the *Per2::Luc KI SKH1* mice.
172 Because waking correlates highly with LMA (Suppl. Fig. 5), we recorded LMA as proxy for
173 wakefulness to avoid invasive EEG/EMG surgery and mice having to adapt to a ca. 2.7 g
174 recorder mounted on the head.

175

176 MODULATING THE AMPLITUDE OF THE SLEEP-WAKE DISTRIBUTION AND ITS 177 INFLUENCE ON PER2 BIOLUMINESCENCE


178 The SCN is the main driver of the circadian sleep-wake distribution because animals in which
179 the SCN is lesioned (SCNx) lack a circadian organization of sleep-wake behavior under
180 constant conditions (Baker et al., 2005; Edgar et al., 1993). Under these conditions, the
181 amplitude of clock gene expression in peripheral organs is significantly reduced, but not
182 eliminated (Akhtar et al., 2002; Curie et al., 2015; Tahara et al., 2012; Sinturel et al., 2021).
183 Given our results in freely behaving mice, we expect that imposing a rhythmic sleep-wake

184 distribution in SCNx mice will reinstate high-amplitude rhythmicity in PER2 bioluminescence.
185 Conversely, reducing the amplitude of the circadian sleep-wake distribution in SCN-intact mice
186 is expected to reduce the amplitude of PER2 bioluminescence. We tested these predictions in
187 two complementary experiments (Suppl. Fig. 1B and -C). In the first experiment, we enforced
188 a daily sleep-wake rhythm in arrhythmic SCNx mice by sleep depriving them for 4h at 24h
189 intervals during 4 subsequent days. In the second experiment, we aimed to acutely reduce the
190 circadian distribution of sleeping and waking in intact mice according to a '2hOnOff' protocol,
191 comprising of twelve 2h SDs each followed by a 2h sleep opportunity 'window' (SOW),
192 previously utilized in the rat (Yasenkov & Deboer, 2010).

193

194 *Repeated sleep deprivations in SCNx mice temporarily reinstate a circadian rhythm in PER2*
195 *bioluminescence*

196 Lesioning the SCN rendered locomotor activity arrhythmic under DD conditions (Suppl. Fig. 6).
197 In arrhythmic SCNx mice, we confirmed that rhythms in PER2 bioluminescence were strongly
198 reduced, but not completely abolished (Fig. 2A, -B, and -C). During the second baseline
199 measurement after SCNx (BSL2 in Fig. 2B), we observed in 2 of the 4 mice erratic high values
200 which we cannot readily explain especially because in the subsequent four SD days the
201 variance in the PER2 bioluminescence signal among mice was again as small as in the earlier
202 recordings (Fig. 2A vs. -B). The erratic values in these 2 mice led to a >10-fold increase in the
203 residual sum of squares, indicating a poorer fit, and to a higher amplitude of the fitted
204 sinewaves in the second compared to the first baseline recording (Fig. 2C, BSL1 vs. BSL2).
205 The repeated SDs induced a robust oscillation in the PER2 bioluminescence signal, restoring
206 amplitude to the levels observed prior to SCN lesioning and higher than those observed in the
207 baseline recordings (Fig. 2C). The latter observation shows that the increased amplitude
208 during the SD did not result from a SD-mediated alignment of different individual phases in
209 baseline. Importantly, the oscillation continued after the end of the SDs while decreasing in
210 amplitude (Fig. 2C).



determined by sinewave fitting [linear mixed model with fixed conditional effects ('Intact', 'BSL', 'SD' and 'REC') and random intercept effect ('Mouse') followed by Tukey's post-hoc tests; intact vs. BSL (BSL1 and BSL2), $p=0.0045$; intact vs. REC, $p=0.0015$; SD vs. BSL: $p=0.0013$; SD vs. REC: $p<0.001$; ★: $p<0.05$].


211
212 *The 2hOnOff protocol reduced the amplitude of the circadian sleep-wake distribution without*
213 *impacting the circadian expression of PER2*

214 In the next experiment, we aimed at reducing the amplitude of the circadian sleep-wake
215 distribution in intact mice using the 2-day 2hOnOff protocol. We measured sleep-wake state
216 and PER2 bioluminescence during baseline conditions, the 2hOnOff procedure and the two
217 recovery days in two cohorts of mice. In the first cohort, PER2 bioluminescence was monitored,
218 and mice were taken out of the RT-Biolumicorder for the 2h SDs. Bioluminescence was
219 therefore quantified only during the SOWs, thus biasing the read-out of PER2 bioluminescence
220 during the 2hOnOff protocol towards levels reached during sleep. A second cohort was
221 implanted with tethered EEG/EMG electrodes to determine the efficacy of the 2hOnOff protocol
222 in reducing the sleep-wake distribution amplitude.

223 As expected, mice exhibited a circadian PER2-bioluminescence rhythm under baseline
224 conditions (Fig. 3A). Contrary to expectation, the 2hOnOff protocol did not significantly
225 decrease the ongoing circadian PER2 oscillation when analyzed at the group level (Fig. 3B).
226 When inspecting the individual responses, 4 out of the 6 mice did show a consistent 27%
227 reduction (range 23-31%) in PER2-bioluminescence amplitude during the 2-day 2hOnOff
228 protocol, while in the remaining two mice amplitude increased by 40% (Fig. 3C). In all 6 mice,
229 PER2 bioluminescence amplitude reverted to baseline values during recovery, irrespective of
230 whether it was increased or decreased during the 2hOnOff protocol. The distinct bimodal,
231 opposing response in amplitude observed among individual mice and the subsequent reverting
232 back to baseline suggests that the 2hOnOff protocol did affect the ongoing PER2
233 bioluminescence rhythm. This phenomenon might relate to factors not accounted for in our
234 experimental design. We will address one potential contributing factor in the modeling section
235 below.

236 We used the second cohort of mice to determine the efficacy with which the 2hOnOff protocol
237 reduced the circadian sleep-wake distribution. In contrast to bioluminescence, the amplitude
238 of the circadian sleep-wake distribution did decrease consistently in all mice (Fig. 3D and -E).
239 The circadian rhythm in the sleep-wake distribution was, however, not eliminated because the
240 sleep obtained during the 2h SDs as well as during the 2h SOWs both varied as a function of
241 time of day (sleep during SDs: average: 12.4%, min-max: 4.9-23.0%; during SOWs: average:
242 54.3%, min-max: 35.7-76.4%). This was especially evident at the beginning of the subjective

243 light phase of day 2, when the average time spent asleep during the SD reached 23%. The
244 sleep obtained during the SDs at this time could be due to an substantial sleep pressure
245 because of lost sleep during day 1 of the 2hOnOff protocol (total time spent asleep/day,
246 mean \pm SEM; baseline: 11.1 \pm 0.1h; 2hOnOff: day 1: 7.3 \pm 0.3h, day 2: 8.6 \pm 0.7h, paired two-tailed
247 t-test, BSL versus 2hOnOff-day 1: $t(7)=8.86$, $p<0.001$; BSL versus 2hOnOff-day2: $t(7)=4.18$,
248 $p=0.004$), 2hOnOff-day1 versus -day2, $t(7)=1.97$, $p=0.09$), combined with the difficulty for the
249 experimenters to visually detect and prevent sleep in pinkish hairless mice under dim-red light
250 conditions.



intervals. A sinewave was fit to the data of the two baseline days, the two 2hOnOff days, and the two recovery days separately (see Materials and Methods). **(B)** The time course of PER2 bioluminescence under baseline conditions and during the 2hOnOff protocol (n=6, data depicted as mean \pm SEM). Light grey squares below the graph mark the 2h SDs. **(C)** The amplitude of the PER2-bioluminescence rhythm decreased in 4 but increased in 2 mice resulting in an overall lack of an effect of the 2hOnOff protocol (paired t-test, $t(5)=0.74$, $p=0.50$; mean \pm SEM; BSL: 0.38 ± 0.03 ; 2hOnOff: 0.35 ± 0.03 ; REC: 0.38 ± 0.01). For all 6 animals the amplitude reverted to baseline during recovery. **(D)** The distribution of waking across the two baseline days (dark grey) and during the 2hOnOff protocol (blue) in EEG-implanted SKH1 mice (n=8, hourly values depicted as mean \pm SEM) and a sinewave fit through the hourly average for visual comparison of BSL to SD. **(E)** Individual estimates of the amplitude of circadian changes in wakefulness during the 2hOnOff protocol were obtained by fitting a sine-wave function to the wakefulness present in consecutive 4h intervals (i.e. SD + SOW). This amplitude was smaller compared to the amplitude obtained in baseline using the same approach (paired t-test, $t(7)=4.9$, $p=0.002$; mean \pm SEM; BSL: 10.4 ± 0.9 ; 2hOnOff: 6.5 ± 1.1). However, a circadian modulation was still present under the 2hOnOff protocol (amplitude >0 , 1-sample t-test, $t(7)=5.8$, $p=0.0007$). The sleep-wake distribution during recovery was not assessed. Note the overall higher levels of wakefulness during 2hOnOff compared to baseline.

251

252 MODELING CIRCADIAN PER2 DYNAMICS

253 The results above demonstrate that both circadian and sleep-wake dependent factors need to
254 be considered when studying PER2 dynamics. To understand how these two factors
255 collectively generate the variance in PER2 bioluminescence, we put our experimental data into
256 a theoretical framework and modeled changes in peripheral PER2 bioluminescence according
257 to a driven harmonic oscillator (Curie et al., 2013). This type of oscillator is not self-sustained
258 but depends on rhythmic forces to set in motion and maintain the oscillation. In the model, we
259 assume the sleep-wake distribution to represent one such force. In the absence of rhythmic
260 forces, the oscillator loses energy resulting in a gradual reduction of its amplitude according to
261 the rate set by its damping constant (γ). Besides amplitude and timing (i.e. phase) of the
262 recurring forces and the damping constant, the oscillatory system is further defined by a string
263 constant (ω_0^2) with the natural angular frequency (ω_0) defining the intrinsic period. Because
264 waking was not quantified alongside bioluminescence in the SCNx and the 2hOnOff
265 experiments, we used locomotor activity (LMA) as a proxy for the driving force provided by
266 wakefulness (\vec{F}_{WAKE}). The 6h SD experiment showed that LMA and time spent awake are
267 strongly correlated and that their hourly dynamics closely changed in parallel (Suppl. Fig. 5A
268 and -B). Moreover, applying the model to this data set (see below) using either wakefulness or

269 LMA as \vec{F}_{WAKE} yielded similar fits (Suppl. Fig. 5C) demonstrating that LMA is an appropriate
270 proxy for wakefulness for the purpose of our model. We performed the analyses at the group
271 level; i.e., the mean LMA level of all mice was used to reflect \vec{F}_{WAKE} , and the free parameters
272 in the model were optimized by fitting the motion of the oscillator to the mean PER2-
273 bioluminescence levels (see Material and Methods). Besides \vec{F}_{WAKE} , we implemented a
274 circadian force to account for the residual PER2 bioluminescence rhythm observed in the
275 SCNx mice (Fig. 2). We assumed that this additional, SCN and sleep-wake independent force
276 reflects a peripheral circadian process (\vec{F}_{PERI}) present in both intact and SCNx mice (Sinturel
277 et al., 2021). This force was modeled as a sinewave with amplitude and phase as free
278 parameters in both experiments while period was set to the period estimated from the baseline
279 PER2-bioluminescence rhythm observed in the SCNx mice (23.7 ± 0.6 h; $n=4$). A schematic
280 overview of the influence of \vec{F}_{PERI} and \vec{F}_{WAKE} on PER2 bioluminescence is presented in Fig. 4A.

281 We first optimized the parameters of the model describing PER2-bioluminescence dynamics
282 in the SCNx experiment (data from Fig. 2), and then predicted PER2-bioluminescence under
283 the 2hOnOff experiment although \vec{F}_{PERI} 's amplitude and phase again required optimization as
284 both differed between the two experiments (non-overlapping 95%-CI for both in Table 1). With
285 the parameters listed in Table 1, the model captured the dynamic changes in PER2
286 bioluminescence in the SCNx experiment with high precision including the residual rhythmicity
287 in baseline, the reinstated pronounced rhythmicity during the 4 SDs, and its subsequent
288 dampening thereafter (Fig. 4B, black line, Table 2). The model also accurately captured
289 average bioluminescence dynamics in the 2hOnOff experiment (Fig. 4C, black line, Table 2).
290 It furthermore predicted an 18% reduction of PER2 bioluminescence amplitude during the
291 2hOnOff protocol compared to baseline (relative amplitudes estimated by the model: 0.31
292 versus 0.38 [a.u.]; Fig. 4C), consistent with our hypotheses and the 27% reduction in PER2
293 bioluminescence amplitude observed in the 4 mice in which amplitude did decrease (see Fig.
294 3C). Finally, we applied the model to predict the peripheral PER2-bioluminescence data
295 obtained in the 6h SD experiment (Fig. 1A) using the parameters of the intact mice in the
296 2hOnOff experiment (Table 1). Also the results of this experiment could be accurately predicted
297 with the model, including the higher PER2-bioluminescence levels reached over the initial
298 recovery hours after SD and the subsequent longer-term reduction in amplitude (Fig. 1A and
299 4D, Table 2). The model could not reliably predict the central PER2-bioluminescence dynamics
300 mainly due to an earlier phase of the central compared to the peripheral signal (Suppl. Fig.
301 7D). Moreover, the increase in PER2 levels immediately following the SD (Fig. 1A) was missed
302 by the model, further underscoring the tissue-specific relationship between time-spent-awake
303 and PER2 requiring the model to be optimized according to the tissue under study.




Figure 4: Mathematical modeling of PER2 bioluminescence dynamics. (A) Schematic view of a driven damped harmonic oscillator. The oscillation (black) is assumed to be driven by two forces: \vec{F}_{WAKE} (blue) and \vec{F}_{PERI} (green). In our model \vec{F}_{WAKE} is based on LMA (here simplified as a square wave) and \vec{F}_{PERI} on a sinewave. Left panels show the individual effect of each force on the oscillator. Both forces start at $t=72$ h and end at $t=216$ h, illustrating the waxing and waning of the resulting rhythm amplitude. Right panel shows the resulting changes in PER2 bioluminescence when combining both forces. Note that combining the two forces increased amplitude and changed the phase of the oscillation. In this example, the amplitude of the peripheral circadian force is flat at beginning and end to illustrate that the oscillation is not self-sustained. (B) Modeling of the SCNx experiment with the full model (Model 3; black line) driving oscillations in PER2-bioluminescence or with either \vec{F}_{WAKE} (Model 1; blue line) or \vec{F}_{PERI} (Model 2; green line) as the only driving

force. Red symbols; 30-minute PER2-bioluminescence averages. Lower graph in blue: 6-minute LMA values. **(C)** Simulation of the PER2-bioluminescence in the 2hOnOff experiment using parameter estimates listed in Table 1. Details as in B. **(D)** Simulation of peripheral PER2-bioluminescence in the 6h SD experiment, using parameter estimates obtained in C (see Table 1).

304

Parameters	SCNx	2hOnOff
γ (damping constant)	0.0155 (0.0103 - 0.0223) [h^{-1}]	
ω_0 (natural angular frequency)	0.288 (0.285 - 0.291) [$\text{rad} \cdot \text{h}^{-1}$]	
β (coefficient \vec{F}_{WAKE})	6.81e-5 (4.48e-5 – 9.01e-5)	
Model Intercept	0.92 (0.90-0.95)	0.91 (0.89 - 0.92)
A (amplitude \vec{F}_{PERI})	2.92e-3 (2.58e-3 - 3.32e-3)	3.87e-3 (3.80e-3 - 4.00e-3)
φ (phase \vec{F}_{PERI})	4.73 (4.6 - 4.85)	2.78 (2.78 - 2.82)

Table 1: **Parameter estimates obtained in the model optimization in the SCNx and 2hOnOff experiments.** Damping constant, natural angular frequency, and the \vec{F}_{WAKE} coefficient were optimized in the SCNx experiment and then used to predict the results of the 2hOnOff experiment. Amplitude and phase of \vec{F}_{PERI} were optimized for both experiments separately. The natural angular frequency defines the intrinsic period of the harmonic oscillation with 0.288 $\text{rad} \cdot \text{h}^{-1}$ corresponding to a period of 21.8h and its square, ω_0^2 , is referred to as the string constant. Phase of the sine function describing \vec{F}_{PERI} is expressed as radians and corresponds to maximum values reached at time 11.8 and 19.4h for the SCNx and 2hOnOff experiment, respectively. Values in parenthesis represent the 95%-CI.

305

306 The model accurately captured peripheral PER2 bioluminescence dynamics under three
 307 different experimental conditions. The model's robust performance prompted us to assess *in*
 308 *silico* whether 1) both forces are required to predict PER2 dynamics, 2) lesioning the SCN
 309 affects the forces exerted on PER2 under undisturbed, DD conditions, and 3) differences in
 310 the circadian phase could predict the opposing response in PER2 amplitude among mice in
 311 the 2hOnOff experiment.

312 To evaluate if \vec{F}_{PERI} and \vec{F}_{WAKE} combined are required to predict PER2 dynamics, we compared
 313 the performance of the model by dropping these two modeling terms; i.e., removing either \vec{F}_{PERI}
 314 or \vec{F}_{WAKE} . Although without \vec{F}_{PERI} the model is unable to capture the residual PER2 rhythmicity
 315 in the baseline of the SCNx experiment (Fig. 4B, 'model 1' until 72h), removing \vec{F}_{PERI} from the
 316 model did not change the coefficient obtained for \vec{F}_{WAKE} (8.25e-5 which is still within the 95%-

317 CI estimated in the full model; see Table 1). However, this simpler model (only 4 free
318 parameters to estimate compared to 6 in the full model) could not reliably predict the
319 bioluminescence data of the SCNx and 2hOnOff experiments (Fig. 4B and -C; blue lines) and
320 fit statistics indicated a poorer fit (i.e., a higher BIC score, see Table 2). Moreover,
321 without \vec{F}_{PERI} , it took longer for the PER2 bioluminescence to reach high amplitude levels
322 compared to the full model, because of \vec{F}_{PERI} being in phase with the timing of the SDs in the
323 full model. With the same strategy we evaluated the model's performance when dropping \vec{F}_{WAKE}
324 (Fig. 4B and -C; green lines). As the sleep-wake distribution no longer affects the model, \vec{F}_{PERI}
325 dynamics are unperturbed throughout the experiment and can therefore be solved as a sine-
326 wave in the differential equation. Fit statistics for the SCNx experiment were poor compared
327 to the full model as the effects of SDs on PER2 amplitude could not be captured (Fig. 4B, Table
328 2). Removing \vec{F}_{WAKE} when modeling the 2hOnOff experiment resulted in BIC scores similar to
329 those obtained with the full model (Table 2), although the amplitude reduction during the
330 2hOnOff protocol could not be captured (Fig. 4C). Together with the modelling of the SCNx
331 and the 6h SD experiments, these results demonstrate that both forces are needed to predict
332 PER2 dynamics under the tested experimental conditions.

333 To answer the second question, we compared the forces driving PER2 bioluminescence in the
334 baseline recordings of the 2hOnOff (intact mice) and the SCNx experiments. The model
335 estimated that the average absolute force (\vec{F}_{WAKE} , \vec{F}_{PERI} , \vec{F}_{γ} , and $\vec{F}\omega_0^2$ combined) exerted on
336 the relative PER2-bioluminescence levels was more than twice as high in intact mice compared
337 to SCNx mice (2.11e-2 vs. 0.90e-2 h-2). This large difference was not due to a difference in
338 \vec{F}_{WAKE} which was somewhat lower in intact mice (2hOnOff vs. SCNx; 2.01e-3 vs. 2.22e-3 h-2).
339 Although \vec{F}_{PERI} was higher by 32% (2.45e-3 vs. 1.85e-3 h-2) this difference did not substantially
340 contribute to the higher amplitude of the PER2 rhythm in intact mice. To illustrate this, we
341 substituted the value of \vec{F}_{PERI} obtained in the 2hOnOff baseline with the lower value obtained
342 in the SCNx baseline, which resulted in a 17% amplitude reduction of the PER2 rhythm. The
343 presence of a circadian sleep-wake distribution impacted PER2 amplitude to a larger extent:
344 running the simulation with the parameters estimated for the 2hOnOff experiment but with the
345 sleep-wake distribution of the SCNx mice resulted in a 32% reduction. Therefore, the circadian
346 sleep-wake organization is an important contributor to high amplitude oscillations in PER2. In
347 the 2hOnOff experiment, the larger PER2 momentum resulted in a 4 times higher spring and
348 damping forces (2hOnOff vs. SCNx; $\vec{F}\omega_0^2$: 19.9e-3 vs. 4.4e-3 h-2; \vec{F}_{γ} : 9.74e-4 vs. 2.52e-4 h-2)
349 that together with the larger \vec{F}_{PERI} underlie the larger average absolute force. Moreover, this
350 analysis demonstrated that the direct effects of \vec{F}_{WAKE} and \vec{F}_{PERI} on PER2 bioluminescence do
351 not depend on an intact SCN and that the magnitude of the two forces are comparable.

352

		BIC	RSS	Bayes Factor (model vs flat)
SCNx	$\vec{F} = \vec{F}_{\text{WAKE}}$	-287.0	11.94	2.47e32
	$\vec{F} = \vec{F}_{\text{PERI}}$	-224.5	13.6	6.48e18
	$\vec{F} = \vec{F}_{\text{WAKE}} + \vec{F}_{\text{PERI}}$	-427.5	8.36	7.87e62
2hOnOff	$\vec{F} = \vec{F}_{\text{WAKE}}$	-28.5	11.96	1.82e24
	$\vec{F} = \vec{F}_{\text{PERI}}$	-536.8	1.29	4.41e86
	$\vec{F} = \vec{F}_{\text{WAKE}} + \vec{F}_{\text{PERI}}$	-540.12	1.27	2.27e87
6h SD peripheral	$\vec{F} = \vec{F}_{\text{WAKE}} + \vec{F}_{\text{PERI}}$	-317.08	2.45	3.56e77

Table 2: **Fitting statistics for the SCNx and 2hOnOff experiments using a single force (\vec{F}_{WAKE} or \vec{F}_{PERI}) or 2 forces combined (\vec{F}_{WAKE} and \vec{F}_{PERI}).** Bayesian Information Criterion (BIC) for each model (lower is better; a BIC difference between two competing models larger than 10 is considered strong support for the model with the lower value). Residual sum of squares (RSS) minimized by the model (lower values reflect a better fit). Support of the driven harmonic model compared to a flat model using Bayes Factor (>100 is considered a 'decisive' support for the driven harmonic model). Values should be compared only within the same experiment because variance and sample size differed among the experiments. Fit statistics for the prediction of the peripheral 6h SD results using the parameters optimized for the 2hOnOff experiment with the full model (Table 1) have been included for completeness.

353

354 Although the model predicted the expected decrease in PER2-bioluminescence rhythm
 355 amplitude in the 2hOnOff experiment, this decrease was not observed in the mean
 356 bioluminescence data. The individual data showed, however, that in 4 mice this intervention
 357 did decrease PER2-bioluminescence amplitude, while in the remaining 2 amplitude increased
 358 (Fig. 3C). With the model we addressed the third question: Do circadian phase differences
 359 predict the opposite effects of the 2hOnOff intervention on amplitude? Surprisingly, when
 360 systematically varying the phase of \vec{F}_{PERI} during the baseline prior to the 2hOnOff intervention
 361 (Suppl. Fig. 7C), we found that at phase advances larger than 2.5h, the model predicted an
 362 increase of PER2 amplitude during the subsequent 2hOnOff protocol instead of a decrease

363 (illustrated in Suppl. Fig. 7A for a 6h phase advance). Circadian phase differences among
364 animals might relate to individual differences in period length of their free-running rhythms that
365 accumulate over time. We did not find evidence for a difference in PER2 bioluminescence or
366 LMA phase at the end of the baseline recording (2.5 days under DD) between animals that
367 showed a decrease in PER2-bioluminescence amplitude compared to animals that showed an
368 increase. However, during the first day of recovery following the 2hOnOff protocol (5.5 days
369 under DD), we observed a ca. 2h phase advance in bioluminescence and 1h phase advance
370 in LMA in the 2 mice that increased their amplitude during the preceding 2hOnOff protocol
371 (Suppl. Fig. 7B, left), compared to the 4 mice for which we observed the anticipated decrease
372 in PER2 amplitude (Suppl. Fig. 7B, right). Whether these differences in phase contributed to
373 the opposite response cannot be answered with the current data set. Nevertheless, the model
374 yielded a perhaps counterintuitive but testable hypothesis by demonstrating that phase angle
375 between the sleep-wake distribution and peripheral circadian clock-gene rhythms is an
376 important variable in predicting outcome and emphasizes the importance of carefully
377 controlling the initial conditions.

378

379

380 Discussion

381 In this study we assessed the contribution of the sleep-wake distribution to circadian peripheral
382 PER2 rhythmicity. We presented three key findings, supporting the notion that sleep-wake
383 state is indeed an important factor in determining the circadian amplitude of peripheral changes
384 in PER2: i) sustained bouts of waking and sleep were associated with increased and
385 decreased PER2 bioluminescence, respectively; ii) repeated SDs temporarily reinstated robust
386 rhythmicity in PER2 bioluminescence in behaviorally arrhythmic mice, and iii) mathematical
387 modeling suggest that PER2 dynamics is best understood as an harmonic oscillator driven by
388 two forces: a sleep-waking dependent force (\vec{F}_{WAKE}) and a SCN-independent and sleep-wake
389 independent, circadian peripheral force (\vec{F}_{PERI}).

390

391 HOW DOES WAKEFULNESS INCREASE PER2?

392 *Per2* transcription can be initiated from its cognate E-boxes by CLOCK/NPAS2:ARNTL. This
393 transcriptional activation is at the core of the TTFL and drives the circadian changes in PER2.
394 Enforced wakefulness not only affects *Per2* levels but also modulates the expression of other
395 components of the TTFL (Mang & Franken, 2015; Hor et al. 2019). The SD-evoked increase
396 in *Per2* expression could therefore be mediated through other clock genes in the circuitry, as
397 was demonstrated by the differential SD-evoked response in *Per2* levels in mice lacking the
398 core clock genes *Npas2* and both *Cry1* and *-2* genes (Franken et al., 2006; Wisor et al., 2002).
399 Apart from a TTFL-mediated activation, *Per2* transcription can be induced by other signaling
400 molecules directly acting on elements within the *Per2* promotor (Schibler et al., 2015). For
401 example, ligand-bound glucocorticoid receptors can induce *Per2* transcription by binding to
402 their glucocorticoid response elements (Cheon et al., 2013; So et al., 2009). Similarly, cAMP
403 response element (CRE)-binding protein (CREB), heat-shock factor 1 (HSF1), and serum-
404 response factor (SRF) can directly activate *Per2* transcription through CREs, heat-shock
405 elements, and CArG-boxes, respectively, present in the *Per2* gene (Gerber et al., 2013;
406 Camille Saini et al., 2012; Tamaru et al., 2011; Travnickova-Bendova et al., 2002). Through
407 these pathways, *Per2* responds to stress, light, temperature, blood-borne systemic cues, and
408 cellular activation as an immediate early gene (IEG). Because of this, *Per2* can appear
409 rhythmic even in the absence of a functional TTFL, provided these signaling pathways fluctuate
410 cyclically (Kornmann et al., 2007). In behaviorally arrhythmic SCNx animals the residual PER2
411 rhythms we observed might similarly result from SCN-independent corticosterone (Andrews,
412 1968) or body temperature (Satinoff & Prosser, 1988) rhythms, or, alternatively, might be
413 TTFL-driven locally (Sinturel et al., 2021).

414 Important for the current study is that several of the pathways known to directly influence *Per2*
415 expression are activated by either spontaneous and/or enforced waking [e.g., corticosterone

416 (Mongrain et al., 2010), temperature (Hoekstra et al., 2019), *Hsf1* and *Srf* (Hor et al., 2019),
417 pCREB (Cirelli & Tononi, 2000)] and are therefore good candidates linking sleep-wake state
418 to changes in PER2. The observed changes in PER2-bioluminescence were rapid and suggest
419 that increases in protein can occur within an hour of spontaneous wakefulness. Other studies
420 document that PER genes can indeed be rapidly transcribed and translated. For instance, a
421 light pulse given at CT14 leads within an hour to a significant increase in *Per2* transcript in the
422 SCN (Yan & Silver, 2002). One study reported a large increase in hepatic *Per2* transcript levels
423 within 1h after food presentation in fasted rats (Wu et al., 2010), underscoring the ability of this
424 transcript to rapidly adapt to homeostatic need. *Per2* translation is not solely dependent on *de*
425 *novo* transcription and, for example in the SCN, light was shown to promote *Per2* translation
426 (R. Cao et al., 2015), suggesting that transcription would not be necessary to increase PER2
427 protein levels. Such mechanism could also underlie the very fast (<30min) 1.5-fold increase in
428 PER2 protein observed in fibroblasts after serum shock (R. Cao et al., 2015).

429 Finally, as the PER2 protein levels measured are the net result of translation and degradation
430 also sleep-wake dependent changes in PER2-degradation rate may contribute both to its
431 increase during wakefulness and its decrease during sleep. PER2 degradation is crucial in
432 setting TTFL period and the timing and stability of the circadian sleep-wake distribution (Chong
433 et al., 2012; D'Alessandro et al., 2017). One established pathway leading to PER2 degradation
434 involves *Casein kinase 1 (Ck1)* mediated phosphorylation (Eide et al., 2005) followed by the
435 recruitment of the ubiquitin ligase *β -transducin repeat-containing proteins (Btrc)* (Masuda et
436 al., 2020; Ohsaki et al., 2008; Reischl et al., 2007). Others kinases, such as *Salt-inducible*
437 *kinase 3 (Sik3)* (Hayasaka et al., 2017) and phosphorylation-independent ubiquitin ligases,
438 such as *Transformed mouse 3T3 cell double minute 2 (Mdm2)* (Liu et al., 2018, p. 2), also
439 target PER2 for degradation. Using a modelling approach to estimate the role of *Btrc* in
440 circadian period length, Reischl (Reischl et al., 2007) estimated a linear decay rate of 0.18/h
441 for PER2 degradation, which is not inconsistent with the approximately 0.10/h net decay rate
442 we observed for the PER2-bioluminescence during sleep. However, the dynamics of PER2
443 degradation have been assessed in a circadian context exclusively, and effects of sleep-wake
444 state have not been quantified previously.

445 The obvious next step is to determine which pathway(s) contributes to the wake-driven
446 changes in PER2 protein. We already established that the sleep-deprivation incurred increase
447 in *Per2* in the forebrain partly depended on glucocorticoids (Mongrain et al., 2010). Along those
448 lines, restoration of daily glucocorticoid rhythms in adrenalectomized rats reinstates PER2
449 rhythms in several extra-SCN brain areas (Segall & Amir, 2010). To determine the contribution
450 of the aforementioned wake-driven factors, a genetic screen could be deployed where one-by-
451 one the regulatory elements in the *Per2* promoter are mutated, and the effect of sleep-wake

452 driven *Per2* changes is assessed. This approach has already been taken for the GRE and
453 CRE elements in the *Per2* promoter to test their respective roles in circadian phase resetting
454 and integrating light information (Cheon et al., 2013; So et al., 2009; Travnickova-Bendova et
455 al., 2002).

456

457 INSIGHTS FROM THE MODEL

458 The model accurately captured the main features of peripheral PER2 dynamics observed in
459 all three experiments, thereby giving further credence to the notion that sleep-wake state
460 importantly contributes to the changes in PER2 observed in the periphery. Moreover, it
461 demonstrated that the large amplitude of the circadian PER2 rhythm in intact mice is likely the
462 result of the momentum gained in the harmonic oscillator through the daily recurring sleep-
463 wake distribution. This is conceptually different from a currently accepted scenario, in which
464 direct and indirect outputs from the SCN assure phase coherence of locally generated self-
465 sustained circadian rhythms (Schibler et al., 2015). According to this model, loss of amplitude
466 observed at the tissue level in SCNx mice is caused by phase dispersion of the continuing
467 rhythms in individual cells. Among the SCN outputs thought to convey phase coherence are
468 feeding, locomotor activity and changes in temperature. Because these outputs all require or
469 are associated with the animal being awake, it can be argued that in both models the circadian
470 sleep-wake distribution is key in keeping peripheral organs rhythmic.

471 The harmonic oscillator model further showed that, although important, the sleep-wake force
472 alone was not sufficient to predict PER2 dynamics. In addition to account for the residual PER2
473 rhythms observed in undisturbed SCNx mice, the SCN-independent and sleep-wake-
474 independent circadian force greatly improved the performance of the model in both
475 experiments. The synergistic effect of both forces (\vec{F}_{PERI} and \vec{F}_{WAKE}) was needed to explain the
476 rapid response to the SDs observed in the SCNx experiment and also in maintaining robust
477 circadian rhythms during the SDs in the 2hOnOff experiment as illustrated in Fig. 4B and -C,
478 respectively. Furthermore, this synergistic effect greatly depended on the relative phase of the
479 two forces as we could illustrate *in silico* for the 2hOnOff experiment: a relative subtle change
480 in the phase of \vec{F}_{PERI} might underlie the increase (instead of the predicted decrease) in PER2
481 amplitude in 2 of the 6 mice recorded.

482 Which pathways set the phase of \vec{F}_{PERI} and whether it is truly independent of \vec{F}_{WAKE} , as
483 assumed in the model, our current results cannot answer. In an earlier modeling effort using a
484 similar approach in SCN-intact, light-dark entrained mice, we also required a second force to
485 correctly predict the phase of the observed rhythm in brain *Per2* expression (Curie et al., 2013).
486 In that publication we based the second force on the pattern of corticosterone production

487 sharply peaking at ZT11 just prior to the light-dark transition. The phase of \vec{F}_{PERI} in the 2hOnOff
488 experiment, which followed a more gradual, sine-wave function of which values became
489 positive shortly after ZT11 (extrapolated from the preceding LD cycle), seems consistent with
490 this. In the SCNx experiment, the phase of \vec{F}_{PERI} was positioned $\sim 7\text{h}$ earlier with a positive
491 driving force starting at the end of each of the SDs. As SD is accompanied by an increase in
492 corticosterone (Mongrain et al., 2010), the phase of \vec{F}_{PERI} could be associated with
493 corticosterone signaling also in the SCNx experiment. Thus in intact mice, the SCN output
494 would dictate the phase of corticosterone production in the adrenals (and thus that of \vec{F}_{PERI}),
495 while in SCNx mice the phase of the corticosterone rhythm can be reset by stressors such as
496 SD. As PER2 and *Per2* levels in the SCN seem insensitive to SD (Curie et al., 2015; Zhang et
497 al., 2016), this could explain why the phase of \vec{F}_{PERI} is maintained in sleep-deprived SCN-intact
498 mice. Moreover, *ex vivo* experiments demonstrated that the adrenal gland can generate bona-
499 fide circadian rhythms in corticosterone release independent of the SCN (Andrews, 1968;
500 Engeland et al., 2018; Kofuji et al., 2016), even though SCNx is generally thought to abolish
501 rhythms in circulating corticosterone levels (Moore & Eichler, 1972). While rhythmic
502 corticosterone release represents a plausible candidate contributing to \vec{F}_{PERI} , especially
503 considering its role in synchronizing peripheral clocks (Balsalobre et al., 2000; Cuesta et al.,
504 2015; Dickmeis, 2009; Le Minh et al., 2001), our current results cannot rule out other sources
505 underlying or contributing to \vec{F}_{PERI} . Above we argued that also wakefulness (i.e., \vec{F}_{WAKE} in the
506 model) could influence peripheral PER2 through corticosterone signaling, further complicating
507 the issue. Indeed, adrenalectomy was found to reduce (but not abolish) the SD-induced
508 increase in *Per2* expression in the forebrain (Mongrain et al., 2010). However, enforced but
509 not spontaneous wakefulness is accompanied by increases in corticosterone and the model
510 could predict PER2 dynamics without having to distinguish between the two types of waking.
511 Therefore, other candidate signals among those listed above must be considered to
512 understand the biological basis of \vec{F}_{PERI} and \vec{F}_{WAKE} .

513 Model optimization yielded an unexpected short 21.8h period for the natural frequency of the
514 PER2 oscillator, which, in addition, differed from the 23.7h period we set for \vec{F}_{PERI} . While in the
515 intact mice of the 2hOnOff experiment it is difficult to independently determine \vec{F}_{PERI} 's period,
516 we estimated a 23.7h period length for the residual PER2 rhythmicity observed during baseline
517 in SCNx mice, which we assume is driven by \vec{F}_{PERI} . In intact mice kept under constant
518 conditions, SCN output drives behavioral sleep-wake rhythms and synchronizes peripheral
519 clock-gene rhythms forcing the entire system to oscillate at the intrinsic period of the SCN.
520 Similarly, in behaviorally arrhythmic SCNx mice, we assume that the period of the observed
521 residual PER2 rhythm reflects that of the only remaining driver, \vec{F}_{PERI} , as \vec{F}_{WAKE} is no longer

522 rhythmic and direct effects of the SCN are absent. *Ex vivo* experiments showed that periods
523 vary among tissues and do not depend on whether tissues were obtained from an intact or
524 SCNx mouse (Cederroth et al., 2019; Yoo et al., 2004), pointing to tissue-specific TTFLs, which
525 we assume to underlie the intrinsic rhythmicity of both \vec{F}_{PERI} and PER2 bioluminescence in our
526 experiments. The difference in period length of \vec{F}_{PERI} and that of the intrinsic PER2 oscillator
527 therefore suggests that \vec{F}_{PERI} is not of renal origin; i.e. the tissue which contributed most to the
528 bioluminescence signal we recorded.

529

530 TISSUE SPECIFICITY OF THE RELATIONSHIP BETWEEN SLEEP-WAKE STATE AND 531 PER2

532 Our data demonstrated that both central and peripheral PER2-bioluminescence dynamics are
533 affected by sleep-wake state, not only after SD but also after spontaneous periods of
534 wakefulness. Despite this general observation, we found clear tissue-specific differences: the
535 6h SD elicited an immediate increase in the central PER2 signal, while in the periphery this
536 increase occurred several hours later, confirming our earlier findings in brain versus liver and
537 kidney (Curie et al. 2015). Tissue specificity was also observed after spontaneous bouts of
538 wakefulness: in the brain, PER2 bioluminescence immediately increased after the animal woke
539 up and continued to do so until the end of the waking bout, whereas in the kidney the increase
540 in PER2 bioluminescence became apparent only 5-10 min after the transition. Similar
541 differences in PER2 dynamics were observed after falling asleep, albeit in opposite direction.
542 Also the model suggested a tissue-specificity, as central dynamics of the 6h SD experiment
543 could not be accurately predicted with the parameters optimized on peripheral PER2
544 bioluminescence data. In its current form, the model describes the global effects of external
545 forces (the sleep-wake distribution and the SCN independent circadian force) on the behavior
546 of the oscillator, but not their acute effects. Translated into molecular terms, the model only
547 makes predictions on the TTFL aspect of PER2 regulation, not on PER2 as an IEG.
548 Accordingly, the model cannot capture the fast changes at the transitions. Similarly, the short-
549 lasting high levels of PER2 observed in the brain immediately after the 6h SD might reflect an
550 IEG response rather than the state of the TTFL oscillator which would explain why the model
551 could not predict it. As sleep-wake states are brain states, it stands to reason that changes in
552 brain PER2 levels capture more of the acute IEG effects than in the periphery. One could test
553 this hypothesis by quantifying the PER2 response after activating a peripheral tissue provided
554 this can be achieved without affecting sleep-wake state as well.

555

556 DO CHANGES IN BIOLUMINESCENCE REFLECT CHANGES IN PER2 LEVELS?

557 The method we implemented to quantify PER2 protein levels presents advantages over
558 previous methods used. It enabled us to acquire data at a time resolution needed to link
559 changes in PER2 to sleep-wake state transitions in individual mice. Moreover, because of the
560 within-subject experimental design, there is a substantial reduction in data variability and, as
561 illustrated with the effects of individual phase on PER2 amplitude in the 2hOnOff experiment,
562 we could assess the presence of individual differences in the initial conditions that might
563 influence experimental outcome. Finally, the number of mice needed for these experiments
564 has been greatly reduced while obtaining better quality data.

565 A limitation of this method is the assumption that changes in bioluminescence reflect changes
566 in PER2 protein levels. Using western blot, we previously validated that changes in
567 bioluminescence during baseline and after a 6h SD indeed reflect changes in PER2 protein
568 (Curie et al., 2015). Nevertheless, substrate availability can importantly contribute to the signal
569 as demonstrated in the experiment in which we delivered luciferin in the drinking water. Even
570 the use of osmotic mini-pumps does not guarantee constant delivery, as its release rate is
571 temperature dependent (Alzet, manufacturer's notes) and bioluminescence's increase during
572 wakefulness might therefore result from the accompanying increase in temperature during this
573 state. Arguments against a possible temperature effect on bioluminescence changes comes
574 from a study in which, using the same osmotic mini-pumps, the expression of two clock genes
575 known to oscillate in anti-phase could be confirmed (Ono et al., 2015), which would not be
576 possible if temperature was the main determinant of bioluminescence. In the current data, the
577 circadian rhythm in wakefulness in the CAG mice was not accompanied by changes in
578 bioluminescence and if anything decreased during the active phase. Moreover, we observed
579 that the circadian rhythms of subcutaneous temperature and bioluminescence are ca. 4h out
580 of phase (data not shown), supporting that the large circadian changes in bioluminescence are
581 not driven by changes in luciferin availability. Nevertheless, to fully exclude that potential rate-
582 limiting availability of luciferin contributed to the fast sleep-wake evoked changes in PER2, we
583 would require confirmation with other techniques sufficiently sensitive to quantify the small but
584 consistent protein changes during sleep and wake.

585

586 CONCLUSIONS

587 In this study, we used a unique combination of methods allowing us to collect high-resolution
588 data of sleep-wake state in conjunction with PER2 levels and found that the sleep-wake
589 distribution profoundly affects PER2 bioluminescence both short- and long-term. Such
590 behavior-dependent plasticity of the time-keeping machinery in tissues peripheral to the SCN
591 enables the organism to respond to challenges as time restricted feeding experiments have
592 demonstrated (Damiola et al., 2000; Saini et al., 2013). Besides its importance in regulating

593 feeding and energy homeostasis (Bass & Takahashi, 2010), the clock circuitry also plays a
594 prominent role in sleep homeostasis (Franken 2013). PER2 seems perfectly suited as an
595 integrator of sleep-wake state and circadian time, because it is sensitive to a variety of sleep-
596 wake driven signals. Our model suggests that having a large amplitude rhythm protects from
597 acute disturbances of sleep as observed in the 2hOnOff experiment, while sleep depriving
598 arrhythmic SCNx mice had immediate and large effects on PER2. These rapid effects could
599 only be achieved through the synergistic effect of a second force that we found to be
600 independent of the SCN and the sleep-wake distribution. The coordination of the sleep-wake
601 force and this second force in the model was critical in predicting the effects of sleep-wake
602 interventions on PER2. Research on the nature of this second force would therefore be
603 important to facilitate phase resetting and normalize disrupted clock gene rhythms under
604 conditions of jet lag and shift work, complementing strategies aimed at altering the timing of
605 the central pacemaker.

606

607 **Acknowledgements**

608 We are greatly indebted to all who helped with the sleep deprivations: Lisa Härrä, Charlotte
609 Hor, and Jeffrey Hubbard, and especially to those who sacrificed their sleep during the
610 graveyard shifts: Kostas Kompotis, Simone Mumbauer, Violeta Castelo-Szekely and Sonia
611 Jimenez. We also thank Sonia for her help with the sleep-wake annotation of EEG/EMG files.

612

613

614 **Material and Methods**

615 MICE AND HOUSING CONDITIONS

616 To measure peripheral PER2 bioluminescence levels we made use of the *Per2::Luc* KI
617 construct (Yoo et al., 2004). The *Per2::Luc* KI construct was originally generated on a
618 C57BL/6J-129 mixed background and subsequently brought onto a C57BL/6J (B6)
619 background by backcrossing for at least 11 generations. These mice were then crossed with
620 outbred SKH1 mice (CrI:SKH1-Hrhr; Charles River) to create hairless *Per2::Luc* KI mice. We
621 used male homozygous *Per2::Luc* KI B6 and hairless heterozygous *Per2::Luc* KI SKH1-B6
622 hybrid (here referred to as SKH1 mice) mice. Mice were kept under a 12 h-light/12 h-dark cycle
623 with light- and dark-onset referred to as Zeitgeber time (ZT)-0 and -12, respectively. Age at
624 time of recording varied between 12 and 24 weeks. Food and water was available *ad libitum*,
625 and after surgery mice were singly housed. All experiments were approved by the Ethical
626 Committee of the State of Vaud Veterinary Office Switzerland under license VD2743 and 3201.

627

628 SOURCE OF BIOLUMINESCENCE AND LUCIFERIN'S ROUTE OF ADMINISTRATION

629 Because *Per2::Luc* KI mice express ubiquitously luciferase and the RT-Biolumicorder cannot
630 discriminate between different sources of bioluminescence, we assessed which peripheral
631 organ(s) was/were the major source of bioluminescence. Two male heterozygous *Per2::Luc*
632 SKH1 mice were implanted with an osmotic mini-pump (model 1002; 35mg/mL luciferin) and
633 five days later lightly anaesthetized with 2.5% isoflurane and imaged for 60 seconds (Xenogen
634 IVIS Lumina II) around ZT6. The main source of dorsal bioluminescence overlapped with the
635 expected location of the kidney, whereas ventrally almost no bioluminescence was detected
636 (see Suppl. Fig. 3A). Most bioluminescence quantified during the experiment is of dorsal origin
637 due to the orientation of the mouse relative to the PMT, suggesting that the kidneys are the
638 main source of peripheral bioluminescence in *Per2::Luc* SKH1 mice.

639 In a second pilot experiment, we investigated the optimal route of luciferin administration.
640 Although luciferin administration via drinking water has been used before to measure
641 bioluminescence (Saini et al., 2013, Iwano et al., 2018, Hall et al., 2018, Sinturel et al. 2021),
642 we were concerned that this route could limit luciferin availability in a circadian fashion because
643 drinking behavior has a strong circadian rhythm (Bainier, Mateo, Felder-Schmittbuhl, &
644 Mendoza, 2017). To address these concerns, we made use of mice expressing constitutively
645 luciferase under control of the synthetic CAG promoter [(Y. A. Cao et al., 2004), Jackson
646 catalog number 008450], thus allowing for testing of circadian fluctuating levels of luciferin.
647 Mice received luciferin via the drinking water or via an osmotic mini-pump and served as their
648 own control. Four male CAG mice were housed for two subsequent experiments in constant
649 darkness in the RT-Biolumicorder. During the first experiment, 0.5 mg/mL luciferin was

650 dissolved in the drinking water. At the end of this experiment, mice received subcutaneously
651 an osmotic mini-pump (Alzet, model 1002) under light anesthesia (isoflurane; 2-4% mixed with
652 O₂) containing 70 mg/mL of luciferin and could recover for two days, before bioluminescence
653 and activity was monitored for the second experiment in the RT-Biolumicorder.

654

655 SURGICAL PROCEDURES AND EXPERIMENTAL DESIGN

656 Experimental design of the 3 main experiments has been depicted in Suppl. Fig. 1 with Panel
657 A illustrating the central and peripheral recordings of PER2 bioluminescence alongside
658 EEG/EMG and LMA before, during, and after a 6h SD, and Panels B and C the SCNx and the
659 2hOnOff experiments, respectively. In the latter 2 experiments peripheral PER2
660 bioluminescence and LMA were recorded.

661 *Sleep-wake state determination in parallel with PER2 bioluminescence*

662 Mice were implanted with electroencephalogram (EEG) and electromyogram (EMG)
663 electrodes under deep ketamine/xylazine anesthesia. Three gold-plated screws (frontal,
664 parietal and cerebellar) were screwed into the skull over the right cerebral hemisphere. Two
665 additional screws were used as anchor screws. For the EMG, a gold wire was inserted into the
666 neck musculature along the back of the skull. For brain delivery of D-luciferin, a cannula (Brain
667 Infusion Kit1, Alzet) was introduced stereotaxically into the right lateral ventricle (1 mm lateral,
668 0.3 mm posterior to bregma and 2.2 mm deep) under deep anesthesia (ketamine/xylazine;
669 intraperitoneally, 75 and 10 mg/kg, respectively), and connected to the mini pump. A
670 depression (diameter 2 mm) was made in (but not through) the skull in a region of the left
671 frontal cortex (approximate coordinates 2 mm lateral to midline, 2 mm anterior to bregma), in
672 which a glass cylinder (length 4.0 mm; diameter 2.0 mm) was positioned and fixed with dental
673 cement. The EMG and three EEG electrodes were subsequently soldered to a connector and
674 cemented to the skull. The cerebellar screw served as a reference for the parietal and frontal
675 screw and the EMG. After the first recovery day, mice were habituated to the weight of the
676 wireless EEG recording system by attaching a dummy of same size and weight to their
677 connector. Two days before habituation to the RT-Biolumicorder, mice were implanted with the
678 osmotic mini-pump (model 1002, Alzet; luciferin 35mg/mL) under light anesthesia. 8-10 days
679 post-surgery, mice were placed in the RT-Biolumicorder at the end of the light phase (~ZT10-
680 ZT12) for two days in LD to habituate to the novel environment. At the end of the second
681 habituation day, the dummy was replaced with a wireless EEG (Neurologger, TSE Systems
682 GmbH). After two-and-a-half days of baseline recording in constant darkness, mice were sleep
683 deprived for six hours at a time they were expected to rest (ZT0 under LD conditions) by gentle
684 handling as described (Mang & Franken, 2012). In short, mice are left undisturbed as long as
685 they do not show signs of sleep. Sleep is prevented by introducing and removing paper tissue,

686 changing the litter, bringing a pipet in the animal's proximity, or gentle tapping of the cage. As
687 opposed to what the term might suggest, mice are not handled. After SD, mice were placed
688 back into the RT-Biolumicorder for the subsequent two recovery days.

689

690 *SCNx experiment*

691 Four SKH1 mice were recorded over the course of the experiment and served as their own
692 control. Briefly, their PER2 bioluminescence rhythm was monitored before SCNx (once), under
693 undisturbed conditions post-SCNx (twice), and after the second measure under SCNx
694 conditions, the mice were subjected to the repeated 4h SDs.

695 Bilateral lesion of the two SCNs was performed stereotaxically (Kopf Instruments, 963LS,
696 Miami Lakes, FL, USA) under ketamine/xylazine anesthesia (intraperitoneal injection, 75 and
697 10 mg/kg, at a volume of 8 mL/kg). Two electrodes (0.3 mm in diameter) were introduced
698 bilaterally at the following coordinates (position of the frontal electrode: anteroposterior using
699 bregma as reference: ± 0.2 mm lateral, +0.5mm bregma, depth: -5.9mm; the second electrode
700 was positioned 0.7 mm posterior to the frontal one). Electrolytic lesions (1 mA, 5 sec) were
701 made using a direct current (DC) lesion device (3500, Ugo Basile, Comerio, Italy). After lesion,
702 mice were housed in constant dark (DD) conditions for at least 10 days to verify absence of
703 circadian organization of overt behavior. Activity was quantified using passive infrared sensors
704 (Visonic SPY 4/ RTE-A, Riverside, CA, USA). ClockLab software (Actimetrics, Wilmette, IL,
705 USA) was used for data acquisition and analyses.

706

707 *Surgeries for tethered EEG/EMG recordings*

708 SKH1 mice (n=8) were implanted with EEG and EMG electrodes as described previously
709 (Mang & Franken, 2012) to determine sleep-wake state. The surgery took place under deep
710 xylazine/ ketamine anesthesia. Briefly, six gold-plated screws (diameter 1.1 mm) were screwed
711 bilaterally into the skull over the frontal and parietal cortices. Two screws served as EEG
712 electrodes and the remaining four screws anchored the electrode connector assembly. As
713 EMG electrodes, two gold wires were inserted into the neck musculature. The EEG and EMG
714 electrodes were soldered to a connector and cemented to the skull. Mice recovered from
715 surgery during several days before they were connected to the recording cables in their home
716 cage for habituation to the cable and their environment, which was at least 6 days prior to the
717 experiment. The habituation to the room and the recovery from the two-day SD-procedure took
718 place under LD 12:12 conditions.

719 During the baseline recording and sleep deprivation days, red light at very low intensity was
720 present to allow the experimenters to observe the mice. Mice were sleep deprived for two
721 hours according to the 'gentle handling' method.

722 *Mice for bioluminescence data collection*

723 SKH1 mice (n=6) were implanted with an osmotic mini-pump (Alzet, 1002, luciferin
724 concentration: 35 mg/mL; blue flow moderator) two days before the habituation. At the end of
725 the light phase (~ZT10-ZT12), mice were moved from their cage to the RT-Biolumicorder for
726 2-3 days of habituation in LD. They were housed for 2.5 days in DD, after which the 2hOnOff
727 protocol was initiated at light onset (ZT0) under the preceding LD conditions. At the start of
728 each SD, mice were moved from the RT-Biolumicorder and placed into a novel cage that was
729 in the same room as the EEG-implanted mice. Fifteen minutes before the end of each SD,
730 mice were brought back to their RT-Biolumicorder cage.

731

732 DATA COLLECTION OF SLEEP-WAKE STATE

733 *Simultaneous recording of sleep-wake state and PER2 bioluminescence*

734 Batteries (Hearing Aid; Ansmann, 312 PR41, 1.45 V 180 mAh) were inserted into the
735 Neurologger. This insertion was timed with the clock of the computer that controlled the RT-
736 Biolumicorder to *post hoc* align the EEG/EMG signals with the bioluminescence signal. In
737 addition, time stamps provided by the SyncBox (NeuroLogger, TSE) were used to verify the
738 start and end time of the EEG/EMG recording. The cerebellar electrode was used as a
739 reference for both EMG and EEG. Data was sampled at 256 Hz. The frontal signal was
740 subtracted from the parietal signal (EDF Browser) to support sleep-wake state determination
741 by enhancing the identification of slow waves and theta waves within the same trace. The data
742 was subsequently loaded in Somnologica (Somnologica 3, MedCare) to determine offline the
743 mouse's behavior as wakefulness, REM sleep or NREM sleep per 4-second epochs based on
744 the EEG and EMG signals. Wakefulness was characterized by EEG activity of mixed frequency
745 and low amplitude, and present but variable muscle tone. NREM sleep (NREM) was defined
746 by synchronous activity in the delta frequency (1-4 Hz) and low and stable muscle tone. REM
747 sleep (REM) was characterized by regular theta oscillations (6-9 Hz) and EMG muscle atonia.

748 *2hOnOff experiment*

749 EEG and EMG signals were recorded continuously for 96 h. The recording started at the
750 beginning of the subjective rest phase, ZT0 of the preceding LD cycle. The analog EEG and
751 EMG signals were amplified (2,000×) and digitized at 2 kHz and subsequently down sampled
752 to 200 Hz and stored. Like the EEG and EMG traces obtained with the Neurologger, the data
753 was imported in Somnologica and sleep-wake state was determined per 4-second epochs.
754 LMA was monitored with passive infrared activity (ActiMetrics, US, Wilmette) and recorded
755 with ClockLab (ActiMetrics, US, Wilmette).

756

757 DATA ANALYSIS

758 *Route of luciferin administration*

759 Circadian time was determined to inspect the circadian changes in bioluminescence relative
760 to locomotor activity. To this end, the period length per mouse was determined based on
761 activity measurements (1-min resolution) by chi-square analysis in ClockLab. Subsequently,
762 the activity and bioluminescence data were folded according to the period. The activity data
763 was averaged per 10 minutes and activity onset was visually determined for each mouse and
764 set at CT12. The aligned activity and bioluminescence data were subsequently averaged per
765 circadian hour.

766 *Spontaneous sleep-wake state and bioluminescence*

767 Bioluminescence and activity were sampled at a resolution of 4-seconds, which is the same
768 resolution of the epochs for sleep-wake state determination. Data processing was
769 subsequently performed in MatLab 2017b (The MathWorks, Inc., Natick, Massachusetts,
770 United States) and R (version 4.0.0). Linear trends were removed from the signal by the build
771 in function *detrend* in Matlab and R (*pracma* package). Subsequently, the bioluminescence
772 signal was expressed relative to the overall mean per mouse to account for inter-individual
773 differences. Changes in PER2 would be expected to occur at a slower rate than 4-seconds.
774 Therefore, sleep-wake and bioluminescence data are averaged per blocks of 3 minutes.

775 For the sleep-wake transition analysis, 3 min intervals in which the mouse was awake for more
776 than 50% (i.e. 23 or more 4s epochs) were deemed awake otherwise as asleep. Based on this
777 new 3-min sleep-wake sequence clear sleep-to-wake and wake-to-sleep transitions were
778 selected according to the following criteria: at least 9 min (three 3-min intervals) of the initial
779 state had to be followed by at least 15 min (five 3-min intervals) of the other state. Transitions
780 were followed both forward and backwards in time as long as state did not change.
781 Bioluminescence for all 3-min intervals of a transition were expressed as a percentage of the
782 level reached at the transition; i.e., the average between the level reached in the last 3 min
783 prior to the transition and the first 3min after the transition. Transitions were aligned according
784 to time of the state transition (time 0) and then averaged first within and then across mice.
785 Average time courses were reported for the longest time spent in state after the transition to
786 which all mice contributed.

787 *2hOnOff experiment*

788 Bioluminescence data obtained five minutes before and ten minutes after the sleep
789 deprivations was excluded from analysis. Subsequent data normalization of the
790 bioluminescence data was as above. To determine the influence of the 2hOnOff protocol on
791 the strength of the ongoing circadian oscillation of the circadian distribution of sleep and wake,

792 as well on PER2 bioluminescence, an estimation of amplitude by sinewave fitting was done
793 (MatLab, $fit = Y_0 + a * \sin(\frac{2*pi}{b} + c)$).

794 *Modeling PER2 bioluminescence with a damped harmonic oscillator*

795 The temporal dynamic of PER2 bioluminescence was modeled according to the equation of
796 motion describing a driven damped harmonic oscillator:

797

$$798 \quad \frac{d^2x}{dt^2} + \gamma \frac{dx}{dt} + \omega_0^2 x = F$$

799

800 where x is the displacement of the oscillator, γ is the damping constant of the model, and ω_0^2
801 the string constant defining the natural frequency of the model. The driving forces used in this
802 model are the locomotor activity (LMA) representing waking \vec{F}_{WAKE} , and a circadian force \vec{F}_{PERI} ,
803 represented as a sinewave. The momentary force exerted on the oscillator is represented as
804 the sum of these two forces (see Fig. 4A):

805

$$806 \quad F(t) = \beta LMA_t + A \sin(\omega t + \varphi)$$

807

808 Where β , A , and φ are respectively the coefficient applied on locomotor activity amount, the
809 amplitude of the circadian sinewave force, and the phase of the circadian sinewave force.
810 These coefficients were the free parameters to be optimized in the model. ω is the angular
811 velocity of the sinewave and was set to $2*pi/23.7$, based on the residual PER2-
812 bioluminescence rhythm present in the baseline of SCNx mice. To solve this equation and
813 optimize for parameters that best describe the observed PER2 bioluminescence, we
814 proceeded as follows: The relative bioluminescence data from both experiments was averaged
815 across mice using 30-minute bins. LMA was averaged across mice using 6-minute bins.
816 Locomotor activity could not be measured directly during sleep deprivations (SD) and was
817 estimated by assessing the increase in LMA during SDs measured in EEG-implanted mice,
818 which was found to be 2.4 times higher compared to average baseline levels. Thus, the SD
819 effect was estimated using 2.4 times the mean activity observed during baseline (i.e. 181.9
820 and 180.2 for the SCNx and 2hOnOff, respectively).

821 To solve the 2nd order ordinary differential equation (ODE) of the driven harmonic oscillator,
822 we transformed it into the following system of two first order ODEs describing the change of
823 position and speed of our oscillator:

824

825

826

827

$$\begin{aligned} x'_1 &= x_2 \\ x'_2 &= F - \gamma x_2 - \omega_0^2 x_1 \end{aligned}$$

828

829 We then used the 4th order Runge-Kutta (RK4) numerical method to approximate the solution
830 using a fixed time step of 0.1 hour. In the SCN_x experiment, initial values of speed ($x_2(0)$) and
831 position ($x_1(0)$) were set to 0. For the 2hOnOff experiment the model was generated for 20
832 days prior experiment to reach a steady-state using replication of LMA observed in baseline
833 (T0-T24). The position and speed of the oscillator at the end of the 20 days were taken as
834 initial values for the fitting. We optimized the model for the following parameters: intercept
835 (equilibrium position of the oscillator), natural frequency, damping constant, and coefficient for
836 the force exerted by LMA, amplitude of circadian force and phase of circadian force. We
837 optimized the fitting minimizing the residual sum of squares (RSS) between predicted position
838 of our model and the observed PER2 bioluminescence level. The box-constrained PORT
839 routines method (nlminb) implemented in the optimx/R package (Nash & Varadhan, 2011) was
840 used to minimize the RSS.

841 The goodness of fit of the model was assessed as follows. We assumed that the model errors
842 follow a normal distribution and computed a Bayesian Information Criterion (BIC) value for the
843 model according to:

844

$$845 \quad BIC = n \ln \left(\frac{RSS}{n} \right) + k \ln (n)$$

846

847 Where n is the number of observations, and k is the number of parameters of the model. We
848 approximated the Bayes Factor (BF) between our model and a flat model (linear model with
849 intercept only) as follow:

850

$$851 \quad BF \approx \exp \left(-\frac{1}{2} (BIC_{flat} - BIC_{model}) \right)$$

852

853 To compute confidence interval of our model parameters we used 500 Monte-Carlo
854 simulations and calculated a confidence interval for our parameters based on 95% empirical
855 quantiles (95%-CI). The method was adapted from the code of Marc Lavielle [Inria Saclay
856 (Xpop) and Ecole Polytechnique (CMAP), Université Paris-Saclay, France] for nonlinear
857 models, available here: <http://sia.webpopix.org/nonlinearRegression.html>

858

859 *Statistics*

860 Statistics were performed in R (version 4.0.0), SAS (version 9.4), and Prism (version 7.0), with
861 the threshold of significance set at $\alpha=0.05$. Performed statistical tests are mentioned in the text
862 and figure legends of the result section.

863


864

865

866

867


868 **Supplementary Figures**



869

870

871




Supplementary Figure 2: **Sleep phenotyping of SKH1 mice.** Four-day time course of time spent asleep and EEG delta power (1-4 Hz) during baseline, 6h sleep deprivation (SD; ZT0-6, t=48-54h; pink area), and recovery in SKH1 mice (n=8) under LD12:12 (grey areas denote the 12h D-periods) conditions. **(A)** NREM sleep (top) and REM sleep (middle), as mean minutes over hourly intervals (± 1 SEM). Also depicted is REM sleep as % of total sleep (NREM + REM sleep; bottom panel). Dark-grey line during SD and recovery represent baseline time course (mean over the 2 baseline days) for comparison. **(B)** Accumulated differences (min/h) from baseline separately for recovery day 1 (t=54-72h) and day 2 (t=72-96h). During recovery day 1 mice accrue ca. $+38.8 \pm 14.6$ min extra NREM sleep, which is again lost during recovery day 2 (-31.5 ± 9.6 min). Mice lose -5.3 ± 1.7 min of REM sleep during first 5 recovery hours after SD. This additional deficit is offset during the remaining of

recovery day 1 resulting in a non-significant increase of 5.5 ± 2.9 min. **(C)** Mean EEG delta power during NREM sleep (± 1 SEM) calculated for 12 and 6 percentiles during the L- and D-periods, respectively (except for L-period recovery day 1; 8 percentiles) to which an equal number of 4s-epochs scored as NREM sleep contributed (per LD period and mouse). Delta power is considered an EEG correlate of sleep need decreasing when sleep prevails (L-period) and increasing when animals are mostly awake (D-periods). SD results in high immediate values that quickly revert to baseline. Red squares underneath curves represent hourly intervals in which values differed from baseline, post-hoc paired t-tests $p < 0.05$.

872


873

874



875


876




877

878


879



880



881



bioluminescence are not able to predict the earlier, sharp increase of PER2 bioluminescence at activity onset, nor the acute increase following sleep deprivation.

882

883

884 **References**

885 Bass, J., & Takahashi, J. S. (2010). Circadian integration of metabolism and energetics.
886 *Science (New York, N.Y.)*, 330(6009), 1349–1354. <https://doi.org/10.1126/science.1195027>

887 Cheon, S., Park, N., Cho, S., & Kim, K. (2013). Glucocorticoid-mediated Period2 induction
888 delays the phase of circadian rhythm. *Nucleic Acids Research*, 41(12), 6161–6174.
889 <https://doi.org/10.1093/nar/gkt307>

890 Chong, S. Y. C., Ptáček, L. J., & Fu, Y.-H. (2012). Genetic insights on sleep schedules: This
891 time, it's PERsonal. *Trends in Genetics*, 28(12), 598–605.
892 <https://doi.org/10.1016/j.tig.2012.08.002>

893 Curie, T., Mongrain, V., Dorsaz, S., Mang, G. M., Emmenegger, Y., & Franken, P. (2013).
894 Homeostatic and circadian contribution to EEG and molecular state variables of sleep
895 regulation. *Sleep*, 36(3), 311–323. <https://doi.org/10.5665/sleep.2440>

896 D'Alessandro, M., Beesley, S., Kim, J. K., Jones, Z., Chen, R., Wi, J., Kyle, K., Vera, D.,
897 Pagano, M., Nowakowski, R., & Lee, C. (2017). Stability of Wake-Sleep Cycles Requires
898 Robust Degradation of the PERIOD Protein. *Current Biology*, 27(22), 3454-3467.e8.
899 <https://doi.org/10.1016/j.cub.2017.10.014>

900 Damiola, F., Le Minh, N., Preitner, N., Kornmann, B., Fleury-Olela, F., & Schibler, U. (2000).
901 Restricted feeding uncouples circadian oscillators in peripheral tissues from the central
902 pacemaker in the suprachiasmatic nucleus. *Genes & Development*, 14(23), 2950–2961.
903 <https://doi.org/10.1101/gad.183500>

904 Eide, E. J., Woolf, M. F., Kang, H., Woolf, P., Hurst, W., Camacho, F., Vielhaber, E. L.,
905 Giovanni, A., & Virshup, D. M. (2005). Control of Mammalian Circadian Rhythm by CKIε-
906 Regulated Proteasome-Mediated PER2 Degradation. *Molecular and Cellular Biology*, 25(7),
907 2795–2807. <https://doi.org/10.1128/MCB.25.7.2795-2807.2005>

908 Hayasaka, N., Hirano, A., Miyoshi, Y., Tokuda, I. T., Yoshitane, H., Matsuda, J., & Fukada, Y.
909 (2017). Salt-inducible kinase 3 regulates the mammalian circadian clock by destabilizing PER2
910 protein. *ELife*, 6, e24779. <https://doi.org/10.7554/eLife.24779>

- 911 Leise, T. L., Wang, C. W., Gitis, P. J., & Welsh, D. K. (2012). Persistent Cell-Autonomous
912 Circadian Oscillations in Fibroblasts Revealed by Six-Week Single-Cell Imaging of PER2::LUC
913 Bioluminescence. *PLoS ONE*, 7(3), e33334. <https://doi.org/10.1371/journal.pone.0033334>
- 914 Liu, J., Zou, X., Gotoh, T., Brown, A. M., Jiang, L., Wisdom, E. L., Kim, J. K., & Finkielstein, C.
915 V. (2018). Distinct control of PERIOD2 degradation and circadian rhythms by the oncoprotein
916 and ubiquitin ligase MDM2. *Science Signaling*, 11(556), eaau0715.
917 <https://doi.org/10.1126/scisignal.aau0715>
- 918 Mang, G. M., & Franken, P. (2015). Genetic dissection of sleep homeostasis. *Current Topics
919 in Behavioral Neurosciences*, 25, 25–63. https://doi.org/10.1007/7854_2013_270
- 920 Masuda, S., Narasimamurthy, R., Yoshitane, H., Kim, J. K., Fukada, Y., & Virshup, D. M.
921 (2020). Mutation of a PER2 phosphodegron perturbs the circadian phosphoswitch.
922 *Proceedings of the National Academy of Sciences*, 117(20), 10888–10896.
923 <https://doi.org/10.1073/pnas.2000266117>
- 924 Nash, J. C., & Varadhan, R. (2011). Unifying Optimization Algorithms to Aid Software System
925 Users: **Optimx** for R. *Journal of Statistical Software*, 43(9).
926 <https://doi.org/10.18637/jss.v043.i09>
- 927 Ohsaki, K., Oishi, K., Kozono, Y., Nakayama, K., Nakayama, K. I., & Ishida, N. (2008). The
928 Role of β -TrCP1 and β -TrCP2 in Circadian Rhythm Generation by Mediating Degradation of
929 Clock Protein PER2. *The Journal of Biochemistry*, 144(5), 609–618.
930 <https://doi.org/10.1093/jb/mvn112>
- 931 Reischl, S., Vanselow, K., Westermarck, P. O., Thierfelder, N., Maier, B., Herzel, H., & Kramer,
932 A. (2007). β -TrCP1-Mediated Degradation of PERIOD2 Is Essential for Circadian Dynamics.
933 *Journal of Biological Rhythms*, 22(5), 375–386. <https://doi.org/10.1177/0748730407303926>
- 934 Saini, C., Liani, A., Curie, T., Gos, P., Kreppel, F., Emmenegger, Y., Bonacina, L., Wolf, J.-P.,
935 Poget, Y.-A., Franken, P., & Schibler, U. (2013). Real-time recording of circadian liver gene
936 expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks.
937 *Genes & Development*, 27(13), 1526–1536. <https://doi.org/10.1101/gad.221374.113>
- 938 Sinturel, F., Gos, P., Petrenko, V., Hagedorn, C., Kreppel, F., Storch, K.-F., Knutti, D., Liani,
939 A., Weitz, C., Emmenegger, Y., Franken, P., Bonacina, L., Dibner, C., & Schibler, U. (2021).
940 Circadian hepatocyte clocks keep synchrony in the absence of a master pacemaker in the
941 suprachiasmatic nucleus or other extrahepatic clocks. *Genes & Development*, 35(5–6), 329–
942 334. <https://doi.org/10.1101/gad.346460.120>

- 943 So, A. Y.-L., Bernal, T. U., Pillsbury, M. L., Yamamoto, K. R., & Feldman, B. J. (2009).
944 Glucocorticoid regulation of the circadian clock modulates glucose homeostasis. *Proceedings*
945 *of the National Academy of Sciences of the United States of America*, *106*(41), 17582–17587.
946 <https://doi.org/10.1073/pnas.0909733106>
- 947
- 948 Akhtar, R. A., Reddy, A. B., Maywood, E. S., Clayton, J. D., King, V. M., Smith, A. G., Gant, T.
949 W., Hastings, M. H., & Kyriacou, C. P. (2002). Circadian Cycling of the Mouse Liver
950 Transcriptome, as Revealed by cDNA Microarray, Is Driven by the Suprachiasmatic Nucleus.
951 *Current Biology*, *12*(7), 540–550. [https://doi.org/10.1016/S0960-9822\(02\)00759-5](https://doi.org/10.1016/S0960-9822(02)00759-5)
- 952 Andrews, R. V. (1968). Temporal secretory responses of cultured hamster adrenals.
953 *Comparative Biochemistry and Physiology*, *26*(1), 179–193. [https://doi.org/10.1016/0010-](https://doi.org/10.1016/0010-406x(68)90324-1)
954 [406x\(68\)90324-1](https://doi.org/10.1016/0010-406x(68)90324-1)
- 955 Baker, F. C., Angara, C., Szymusiak, R., & McGinty, D. (2005). Persistence of sleep-
956 temperature coupling after suprachiasmatic nuclei lesions in rats. *American Journal of*
957 *Physiology. Regulatory, Integrative and Comparative Physiology*, *289*(3), R827-838.
958 <https://doi.org/10.1152/ajpregu.00093.2005>
- 959 Balsalobre, A., Brown, S. A., Marcacci, L., Tronche, F., Kellendonk, C., Reichardt, H. M.,
960 Schütz, G., & Schibler, U. (2000). Resetting of circadian time in peripheral tissues by
961 glucocorticoid signaling. *Science (New York, N.Y.)*, *289*(5488), 2344–2347.
962 <https://doi.org/10.1126/science.289.5488.2344>
- 963 Bass, J., & Takahashi, J. S. (2010). Circadian integration of metabolism and energetics.
964 *Science (New York, N.Y.)*, *330*(6009), 1349–1354. <https://doi.org/10.1126/science.1195027>
- 965 Cao, R., Gkogkas, C. G., de Zavalía, N., Blum, I. D., Yanagiya, A., Tsukumo, Y., Xu, H., Lee,
966 C., Storch, K.-F., Liu, A. C., Amir, S., & Sonenberg, N. (2015). Light-regulated translational
967 control of circadian behavior by eIF4E phosphorylation. *Nature Neuroscience*, *18*(6), 855–862.
968 <https://doi.org/10.1038/nn.4010>
- 969 Cao, Y.-A., Wagers, A. J., Beilhack, A., Dusich, J., Bachmann, M. H., Negrin, R. S., Weissman,
970 I. L., & Contag, C. H. (2004). Shifting foci of hematopoiesis during reconstitution from single
971 stem cells. *Proceedings of the National Academy of Sciences of the United States of America*,
972 *101*(1), 221–226. <https://doi.org/10.1073/pnas.2637010100>
- 973 Castelo-Szekely, V., Arpat, A. B., Janich, P., & Gatfield, D. (2017). Translational contributions
974 to tissue specificity in rhythmic and constitutive gene expression. *Genome Biology*, *18*(1), 116.
975 <https://doi.org/10.1186/s13059-017-1222-2>

- 976 Cederroth, C. R., Park, J.-S., Basinou, V., Weger, B. D., Tserga, E., Sarlus, H., Magnusson,
977 A. K., Kadri, N., Gachon, F., & Canlon, B. (2019). Circadian Regulation of Cochlear Sensitivity
978 to Noise by Circulating Glucocorticoids. *Current Biology: CB*, 29(15), 2477-2487.e6.
979 <https://doi.org/10.1016/j.cub.2019.06.057>
- 980 Cheon, S., Park, N., Cho, S., & Kim, K. (2013). Glucocorticoid-mediated Period2 induction
981 delays the phase of circadian rhythm. *Nucleic Acids Research*, 41(12), 6161–6174.
982 <https://doi.org/10.1093/nar/gkt307>
- 983 Cirelli, C., & Tononi, G. (2000). Differential expression of plasticity-related genes in waking and
984 sleep and their regulation by the noradrenergic system. *The Journal of Neuroscience: The*
985 *Official Journal of the Society for Neuroscience*, 20(24), 9187–9194.
- 986 Cuesta, M., Cermakian, N., & Boivin, D. B. (2015). Glucocorticoids entrain molecular clock
987 components in human peripheral cells. *FASEB Journal: Official Publication of the Federation*
988 *of American Societies for Experimental Biology*, 29(4), 1360–1370.
989 <https://doi.org/10.1096/fj.14-265686>
- 990 Curie, T., Maret, S., Emmenegger, Y., & Franken, P. (2015). In Vivo Imaging of the Central
991 and Peripheral Effects of Sleep Deprivation and Suprachiasmatic Nuclei Lesion on PERIOD-2
992 Protein in Mice. *Sleep*, 38(9), 1381–1394. <https://doi.org/10.5665/sleep.4974>
- 993 Curie, T., Mongrain, V., Dorsaz, S., Mang, G. M., Emmenegger, Y., & Franken, P. (2013).
994 Homeostatic and circadian contribution to EEG and molecular state variables of sleep
995 regulation. *Sleep*, 36(3), 311–323. <https://doi.org/10.5665/sleep.2440>
- 996 Daan, S., Beersma, D. G., & Borbély, A. A. (1984). Timing of human sleep: Recovery process
997 gated by a circadian pacemaker. *The American Journal of Physiology*, 246(2 Pt 2), R161-183.
998 <https://doi.org/10.1152/ajpregu.1984.246.2.R161>
- 999 Damiola, F., Le Minh, N., Preitner, N., Kornmann, B., Fleury-Olela, F., & Schibler, U. (2000).
1000 Restricted feeding uncouples circadian oscillators in peripheral tissues from the central
1001 pacemaker in the suprachiasmatic nucleus. *Genes & Development*, 14(23), 2950–2961.
1002 <https://doi.org/10.1101/gad.183500>
- 1003 Dickmeis, T. (2009). Glucocorticoids and the circadian clock. *The Journal of Endocrinology*,
1004 200(1), 3–22. <https://doi.org/10.1677/JOE-08-0415>
- 1005 Edgar, D. M., Dement, W. C., & Fuller, C. A. (1993). Effect of SCN lesions on sleep in squirrel
1006 monkeys: Evidence for opponent processes in sleep-wake regulation. *The Journal of*
1007 *Neuroscience: The Official Journal of the Society for Neuroscience*, 13(3), 1065–1079.

- 1008 Engeland, W. C., Massman, L., Mishra, S., Yoder, J. M., Leng, S., Pignatti, E., Piper, M. E.,
1009 Carlone, D. L., Breault, D. T., & Kofuji, P. (2018). The Adrenal Clock Prevents Aberrant Light-
1010 Induced Alterations in Circadian Glucocorticoid Rhythms. *Endocrinology*, *159*(12), 3950–3964.
1011 <https://doi.org/10.1210/en.2018-00769>
- 1012 Franken, P. (2013). A role for clock genes in sleep homeostasis. *Current Opinion in*
1013 *Neurobiology*, *23*(5), 864–872. <https://doi.org/10.1016/j.conb.2013.05.002>
- 1014 Franken, P., Dudley, C. A., Estill, S. J., Barakat, M., Thomason, R., O'Hara, B. F., & McKnight,
1015 S. L. (2006). NPAS2 as a transcriptional regulator of non-rapid eye movement sleep: Genotype
1016 and sex interactions. *Proceedings of the National Academy of Sciences of the United States*
1017 *of America*, *103*(18), 7118–7123. <https://doi.org/10.1073/pnas.0602006103>
- 1018 Franken, P., Thomason, R., Heller, H. C., & O'Hara, B. F. (2007). A non-circadian role for
1019 clock-genes in sleep homeostasis: A strain comparison. *BMC Neuroscience*, *8*, 87.
1020 <https://doi.org/10.1186/1471-2202-8-87>
- 1021 Gerber, A., Esnault, C., Aubert, G., Treisman, R., Pralong, F., & Schibler, U. (2013). Blood-
1022 borne circadian signal stimulates daily oscillations in actin dynamics and SRF activity. *Cell*,
1023 *152*(3), 492–503. <https://doi.org/10.1016/j.cell.2012.12.027>
- 1024 Hastings, M. H., Maywood, E. S., & Brancaccio, M. (2018). Generation of circadian rhythms in
1025 the suprachiasmatic nucleus. *Nature Reviews. Neuroscience*, *19*(8), 453–469.
1026 <https://doi.org/10.1038/s41583-018-0026-z>
- 1027 Hastings, M. H., Maywood, E. S., & Brancaccio, M. (2019). The Mammalian Circadian Timing
1028 System and the Suprachiasmatic Nucleus as Its Pacemaker. *Biology*, *8*(1).
1029 <https://doi.org/10.3390/biology8010013>
- 1030 Hoekstra, M. M., Emmenegger, Y., Hubbard, J., & Franken, P. (2019). Cold-inducible RNA-
1031 binding protein (CIRBP) adjusts clock-gene expression and REM-sleep recovery following
1032 sleep deprivation. *eLife*, *8*. <https://doi.org/10.7554/eLife.43400>
- 1033 Hor, C. N., Yeung, J., Jan, M., Emmenegger, Y., Hubbard, J., Xenarios, I., Naef, F., & Franken,
1034 P. (2019). Sleep–wake-driven and circadian contributions to daily rhythms in gene expression
1035 and chromatin accessibility in the murine cortex. *Proceedings of the National Academy of*
1036 *Sciences*, *116*(51), 25773–25783. <https://doi.org/10.1073/pnas.1910590116>
- 1037 Kofuji, P., Mure, L. S., Massman, L. J., Purrier, N., Panda, S., & Engeland, W. C. (2016).
1038 Intrinsically Photosensitive Retinal Ganglion Cells (ipRGCs) Are Necessary for Light
1039 Entrainment of Peripheral Clocks. *PloS One*, *11*(12), e0168651.
1040 <https://doi.org/10.1371/journal.pone.0168651>

- 1041 Kornmann, B., Schaad, O., Bujard, H., Takahashi, J. S., & Schibler, U. (2007). System-driven
1042 and oscillator-dependent circadian transcription in mice with a conditionally active liver clock.
1043 *PLoS Biology*, 5(2), e34. <https://doi.org/10.1371/journal.pbio.0050034>
- 1044 Le Minh, N., Damiola, F., Tronche, F., Schütz, G., & Schibler, U. (2001). Glucocorticoid
1045 hormones inhibit food-induced phase-shifting of peripheral circadian oscillators. *The EMBO*
1046 *Journal*, 20(24), 7128–7136. <https://doi.org/10.1093/emboj/20.24.7128>
- 1047 Mang, G. M., & Franken, P. (2012). Sleep and EEG Phenotyping in Mice. *Current Protocols in*
1048 *Mouse Biology*, 2(1), 55–74. <https://doi.org/10.1002/9780470942390.mo110126>
- 1049 Mang, G. M., & Franken, P. (~~2015~~2013). Genetic dissection of sleep homeostasis. *Current*
1050 *Topics in Behavioral Neurosciences*, 25, 25–63. https://doi.org/10.1007/7854_2013_270
- 1051 Maret, S., Dorsaz, S., Gurcel, L., Pradervand, S., Petit, B., Pfister, C., Hagenbuchle, O.,
1052 O’Hara, B. F., Franken, P., & Tafti, M. (2007). Homer1a is a core brain molecular correlate of
1053 sleep loss. *Proceedings of the National Academy of Sciences of the United States of America*,
1054 104(50), 20090–20095. <https://doi.org/10.1073/pnas.0710131104>
- 1055 Möller-Levet, C. S., Archer, S. N., Bucca, G., Laing, E. E., Slak, A., Kabiljo, R., Lo, J. C. Y.,
1056 Santhi, N., von Schantz, M., Smith, C. P., & Dijk, D.-J. (2013). Effects of insufficient sleep on
1057 circadian rhythmicity and expression amplitude of the human blood transcriptome.
1058 *Proceedings of the National Academy of Sciences of the United States of America*, 110(12),
1059 E1132-1141. <https://doi.org/10.1073/pnas.1217154110>
- 1060 Mongrain, V., Hernandez, S. A., Pradervand, S., Dorsaz, S., Curie, T., Hagiwara, G., Gip, P.,
1061 Heller, H. C., & Franken, P. (2010). Separating the contribution of glucocorticoids and
1062 wakefulness to the molecular and electrophysiological correlates of sleep homeostasis. *Sleep*,
1063 33(9), 1147–1157. <https://doi.org/10.1093/sleep/33.9.1147>
- 1064 Moore, R. Y., & Eichler, V. B. (1972). Loss of a circadian adrenal corticosterone rhythm
1065 following suprachiasmatic lesions in the rat. *Brain Research*, 42(1), 201–206.
1066 [https://doi.org/10.1016/0006-8993\(72\)90054-6](https://doi.org/10.1016/0006-8993(72)90054-6)
- 1067 Ohnishi, N., Tahara, Y., Kuriki, D., Haraguchi, A., & Shibata, S. (2014). Warm water bath
1068 stimulates phase-shifts of the peripheral circadian clocks in PER2::LUCIFERASE mouse. *PLoS*
1069 *One*, 9(6), e100272. <https://doi.org/10.1371/journal.pone.0100272>
- 1070 Ono, D., Honma, K., & Honma, S. (2015). Circadian and ultradian rhythms of clock gene
1071 expression in the suprachiasmatic nucleus of freely moving mice. *Scientific Reports*, 5, 12310.
1072 <https://doi.org/10.1038/srep12310>

- 1073 Saini, C., Liani, A., Curie, T., Gos, P., Kreppel, F., Emmenegger, Y., Bonacina, L., Wolf, J.-P.,
1074 Poget, Y.-A., Franken, P., & Schibler, U. (2013). Real-time recording of circadian liver gene
1075 expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks.
1076 *Genes & Development*, 27(13), 1526–1536. <https://doi.org/10.1101/gad.221374.113>
- 1077 Saini, Camille, Morf, J., Stratmann, M., Gos, P., & Schibler, U. (2012). Simulated body
1078 temperature rhythms reveal the phase-shifting behavior and plasticity of mammalian circadian
1079 oscillators. *Genes & Development*, 26(6), 567–580. <https://doi.org/10.1101/gad.183251.111>
- 1080 Satinoff, E., & Prosser, R. A. (1988). Suprachiasmatic nuclear lesions eliminate circadian
1081 rhythms of drinking and activity, but not of body temperature, in male rats. *Journal of Biological*
1082 *Rhythms*, 3(1), 1–22. <https://doi.org/10.1177/074873048800300101>
- 1083 Schibler, U., Gotic, I., Saini, C., Gos, P., Curie, T., Emmenegger, Y., Sinturel, F., Gosselin, P.,
1084 Gerber, A., Fleury-Olela, F., Rando, G., Demarque, M., & Franken, P. (2015). Clock-Talk:
1085 Interactions between Central and Peripheral Circadian Oscillators in Mammals. *Cold Spring*
1086 *Harbor Symposia on Quantitative Biology*, 80, 223–232.
1087 <https://doi.org/10.1101/sqb.2015.80.027490>
- 1088 Segall, L. A., & Amir, S. (2010). Exogenous corticosterone induces the expression of the clock
1089 protein, PERIOD2, in the oval nucleus of the bed nucleus of the stria terminalis and the central
1090 nucleus of the amygdala of adrenalectomized and intact rats. *Journal of Molecular*
1091 *Neuroscience: MN*, 42(2), 176–182. <https://doi.org/10.1007/s12031-010-9375-4>
- 1092 So, A. Y.-L., Bernal, T. U., Pillsbury, M. L., Yamamoto, K. R., & Feldman, B. J. (2009).
1093 Glucocorticoid regulation of the circadian clock modulates glucose homeostasis. *Proceedings*
1094 *of the National Academy of Sciences of the United States of America*, 106(41), 17582–17587.
1095 <https://doi.org/10.1073/pnas.0909733106>
- 1096 Tahara, Y., Kuroda, H., Saito, K., Nakajima, Y., Kubo, Y., Ohnishi, N., Seo, Y., Otsuka, M.,
1097 Fuse, Y., Ohura, Y., Komatsu, T., Moriya, Y., Okada, S., Furutani, N., Hirao, A., Horikawa, K.,
1098 Kudo, T., & Shibata, S. (2012). In vivo monitoring of peripheral circadian clocks in the mouse.
1099 *Current Biology: CB*, 22(11), 1029–1034. <https://doi.org/10.1016/j.cub.2012.04.009>
- 1100 Tamaru, T., Hattori, M., Honda, K., Benjamin, I., Ozawa, T., & Takamatsu, K. (2011).
1101 Synchronization of circadian Per2 rhythms and HSF1-BMAL1:CLOCK interaction in mouse
1102 fibroblasts after short-term heat shock pulse. *PloS One*, 6(9), e24521.
1103 <https://doi.org/10.1371/journal.pone.0024521>
- 1104 Travnickova-Bendova, Z., Cermakian, N., Reppert, S. M., & Sassone-Corsi, P. (2002). Bimodal
1105 regulation of mPeriod promoters by CREB-dependent signaling and CLOCK/BMAL1 activity.

- 1106 *Proceedings of the National Academy of Sciences of the United States of America*, 99(11),
1107 7728–7733. <https://doi.org/10.1073/pnas.102075599>
- 1108 van der Vinne, V., Swoap, S. J., Vajtay, T. J., & Weaver, D. R. (2018). Desynchrony between
1109 brain and peripheral clocks caused by CK1 δ/ϵ disruption in GABA neurons does not lead to
1110 adverse metabolic outcomes. *Proceedings of the National Academy of Sciences of the United*
1111 *States of America*, 115(10), E2437–E2446. <https://doi.org/10.1073/pnas.1712324115>
- 1112 Vassalli, A., & Franken, P. (2017). Hypocretin (orexin) is critical in sustaining theta/gamma-
1113 rich waking behaviors that drive sleep need. *Proceedings of the National Academy of Sciences*
1114 *of the United States of America*, 114(27), E5464–E5473.
1115 <https://doi.org/10.1073/pnas.1700983114>
- 1116 Wisor, J. P., O'Hara, B. F., Terao, A., Selby, C. P., Kilduff, T. S., Sancar, A., Edgar, D. M., &
1117 Franken, P. (2002). A role for cryptochromes in sleep regulation. *BMC Neuroscience*, 3, 20.
1118 <https://doi.org/10.1186/1471-2202-3-20>
- 1119 Wu, T., Ni, Y., Kato, H., & Fu, Z. (2010). Feeding-induced rapid resetting of the hepatic
1120 circadian clock is associated with acute induction of Per2 and Dec1 transcription in rats.
1121 *Chronobiology International*, 27(1), 1–18. <https://doi.org/10.3109/07420520903398625>
- 1122 Yan, L., & Silver, R. (2002). Differential induction and localization of mPer1 and mPer2 during
1123 advancing and delaying phase shifts. *The European Journal of Neuroscience*, 16(8), 1531–
1124 1540. <https://doi.org/10.1046/j.1460-9568.2002.02224.x>
- 1125 Yasenkov, R., & Deboer, T. (2010). Circadian regulation of sleep and the sleep EEG under
1126 constant sleep pressure in the rat. *Sleep*, 33(5), 631–641.
1127 <https://doi.org/10.1093/sleep/33.5.631>
- 1128 Yoo, S.-H., Yamazaki, S., Lowrey, P. L., Shimomura, K., Ko, C. H., Buhr, E. D., Siepkka, S. M.,
1129 Hong, H.-K., Oh, W. J., Yoo, O. J., Menaker, M., & Takahashi, J. S. (2004).
1130 PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent
1131 circadian oscillations in mouse peripheral tissues. *Proceedings of the National Academy of*
1132 *Sciences*, 101(15), 5339–5346. <https://doi.org/10.1073/pnas.0308709101>
- 1133 Zhang, B., Gao, Y., Li, Y., Yang, J., & Zhao, H. (2016). Sleep Deprivation Influences Circadian
1134 Gene Expression in the Lateral Habenula. *Behavioural Neurology*, 2016, 7919534.
1135 <https://doi.org/10.1155/2016/7919534>
- 1136
- 1137